

STAGING ILLNESS AND TREATMENT:





ASCP
AMERICAN SOCIETY OF
CLINICAL PSYCHOPHARMACOLOGY

Dear Colleagues:

On behalf of the American Society of Clinical Psychopharmacology (ASCP), we are very pleased to welcome you to this year's ASCP Annual Meeting. In 2010, several decisions were made that allowed ASCP to reinvent NCDEU as "the New NCDEU." Over the last four years "the New NCDEU" has been quite successful. When the ASCP Board and the ASCP/NCDEU Steering Committee decided to rename the meeting to the "ASCP Annual Meeting," we all knew this was the right decision.

The ASCP is proud to sponsor the meeting, now in its 55th year.

Psychopharmacology is an exciting field undergoing dramatic changes, with the identification of new molecular targets and the development of novel compounds. Our Society keeps its members abreast of such innovations. Our annual meeting serves as the vehicle for the dissemination of cutting edge psychopharmacology research. We will continue to develop ways for members to feel more connected with our Society and to include more clinically focused symposia.

Another major goal for ASCP is to increase its visibility to those interested in the practice of psychopharmacology, thereby helping our membership grow. With over 1,000 annual attendees, the meeting has also become a key opportunity for networking, planning and to develop the next generation of clinical researchers.

A very special thank you to the members of the ASCP/NCDEU Steering and ASCP Program Committees for their critical role in the success of the meeting. We are all looking forward to an exciting and highly informative ASCP Annual Meeting.

Maurizio Fava, M.D.
President

American Society of Clinical Psychopharmacology

Welcome to the ASCP Annual Meeting

On behalf of the ASCP Annual Meeting Steering and Program Committees, we are delighted to welcome you to the ASCP Annual Meeting. The ASCP is committed to continue building on the past success of NCDEU with program innovation while preserving the rich history of this meeting. Below are some of the highlights of the 2015 meeting.

The annual meeting brings together academic investigators, industry scientists, U.S. and international regulators, National Institutes of Health (NIH) and other professionals who work in drug development and clinical trials.

- **2015 Program Highlights**

- Sunday, June 21st
 - Latin America Psychopharmacology Update
- Monday, June 22nd
 - Conference Opening
 - Pharma Pipeline: 13 presentations of Phase 1 and Phase 2 developments
- Tuesday, June 23rd
 - 16th Annual Fun Run/Walk
 - Regulatory Plenary: *FDA and EMA Approaches to Innovation in Clinical Trials*
 - ASCP Lifetime Awardee Talk
 - Poster Session I
 - ASCP Reception
- Wednesday, June 24th
 - Keynote Plenary Session: *Changing the Paradigm from Diagnose and Treat to Predict and Prevent*
 - NIH Institute Directors Plenary
 - Poster Session II
 - Clinical Updates in Pharmacology
 - Workshops
- Thursday, June 25th
 - Regulatory Wrap-Up Plenary with FDA and EMA regulators
- Throughout the meeting
 - NIMH, NIDA, and NCCAM panels
- The New Investigator Program
 - A closed workshop for 21 New Investigators and informal breakfast sessions
- Workshops: 2 hour intensive interactive sessions focused on problems and solutions
 - Tuesday and Wednesday Afternoons
- ***Clinical Track** – sessions focused on topics of immediate clinical relevance

- **Organization**

- The meeting is sponsored by the American Society of Clinical Psychopharmacology (ASCP).
 - The Steering Committee organizes the meeting.
 - The Program Committee evaluates submitted proposals and develops program innovations.
- NIH collaborations:
 - NIMH - National Institute of Mental Health
 - NIDA - National Institute of Drug Abuse
 - NIAAA - National Institute on Alcohol Abuse and Alcoholism
 - NCCAM - National Center for Complementary and Alternative Medicine
 - CSR - Center for Scientific Review
 - NCATS - National Center for Advancing Translational Sciences
- Regulatory agency collaborations:
 - Food and Drug Administration (FDA)
 - European Medicines Authority (EMA)
- Parthenon Management Group organizes the ASCP Annual Meeting.

- **And remember**

- The Opening Reception is Tuesday, June 23rd from 7:15 pm – 8:15 pm.
- The Fun Run/Walk is Tuesday, June 23rd at 6:45 am. All are welcome to join!

The ASCP Annual Meeting is an opportunity for education and networking. We welcome your suggestions to make the event even better. Seek us out during the meeting or provide your views by completing the evaluation form.


Best Regards,



Hussein Manji, M.D., FRCP
Steering Committee Co-Chair



Alan Gelenberg, M.D.
Program Committee Co-Chair




Michael E. Thase, M.D.
Steering Committee Co-Chair




Holly A. Swartz, M.D.
Program Committee Co-Chair

Loews Miami Beach Hotel

Second Level



Third Level



Award Winners and Featured Speakers	5
Acknowledgements	19
Meeting Announcements.....	25
Sunday, June 21, 2015.....	29
Monday, June 22, 2015	35
Tuesday, June 23, 2015.....	45
Wednesday, June 24, 2015	57
Thursday, June 25, 2015	67
Poster Session I.....	73
Poster Session II.....	87
Author Index	101

**DISCLOSURES FOR ALL ASCP PRESENTERS
CAN BE VIEWED AT WWW.ASCPMEETING.ORG**

[illegible]

Recipient of the Donald Klein Lifetime Achievement Award



Nina Schooler, Ph.D.
SUNY Downstate Medical Center

Dr. Schooler is a Professor of Psychiatry and Behavioral Sciences at State University of New York Downstate Medical Center, Brooklyn, NY and also a Senior Research Scientist at The Zucker Hillside Hospital in Glen Oaks, NY. Her research focuses on treatment of schizophrenia from its earliest identification to its long-term course and outcomes.

Her Ph.D. is in Social Psychology (Columbia University in New York), but her research professional career has been focused on clinical psychopharmacology. She had the good fortune to begin professional work at the Psychopharmacology Service Center of the National Institute of Mental Health (NIMH), a unit created and led by Jonathan Cole. That start allowed her to advance to leadership positions at the NIMH and develop and lead multicenter clinical trials of medication and psychosocial treatments for schizophrenia. After leaving NIMH, she joined the Department of Psychiatry at the University of Pittsburgh, Western Psychiatric Institute and Clinic (WPIC) where she directed the Psychosis Research Program and became a Professor of Psychiatry and Psychology. Her work with first-episode psychosis started at WPIC, but she also continued research on longer-term treatment and pharmacological treatment of more persistently psychotic patients. Dr. Schooler later served as Director of Psychiatry Research at the Zucker Hillside Hospital, continuing research with first episode psychosis, long-term treatments and developing a focus on negative symptoms in schizophrenia. Her current work continues the scientific themes developed over the years including first episode psychosis and long term-treatment with a richer understanding of the need to move from the view of long-term treatment as “maintenance” to that of remission and recovery. Multi-center studies have been at the center of her work as is the inherent need for collaborations that these studies represent.

Dr. Schooler is a fellow of the American College of Neuropsychopharmacology, the Collegium Internationale Neuropsychopharmacologicum (CINP), the American Psychological Association, and the American Psychological Society. She has been President of the American Psychopathological Association and the Association for Clinical Psychosocial Research, and has served as an elected Councilor of the CINP and the Executive Committee of the International Society for CNS Clinical Trials Methodology (ISCTM). Dr. Schooler chaired the Steering Committee for the ASCP (NCDEU) Annual Meeting. She has published in the peer-reviewed psychiatric literature and edited volumes relating to psychiatric clinical trials, clinical assessment, and research methods.

Her prior awards include the Gralnick Foundation-High Point Hospital Award from the Education and Research Foundation of the National Association of Psychiatric Health Systems, the Alexander Gralnick Research Investigator Award from the American Psychological Foundation, the Samuel Hamilton Award from the American Psychopathological Association and the Andrew Leon Career Research Award from the International Society for CNS Clinical Trials and Methodology.

Recipient of the Paul Wender Best Paper in the Journal of Clinical Psychiatry Award



K.N. Roy Chengappa, M.D.
University of Pittsburgh Medical Center

Nominated for: *Smoking Cessation in Bipolar Disorder, Double-blind, Placebo-controlled Study*

K.N. Roy Chengappa, M.D.; Kenneth A. Perkins, Ph.D.; Jaspreet S. Brar, MBBS, Ph.D., MPH; Patricia J. Schlicht, RN, MA; Scott R. Turkin, M.D.; Michelle L. Hetrick, MA, NCC, LPC; Michele D. Levine, Ph.D.; and Tony P. George, M.D.; Varenicline, *J Clin Psychiatry* 2014; 75 (7):765-772.

K.N. Roy Chengappa, M.D., is a Professor of Psychiatry at the University Of Pittsburgh School of Medicine and the Western Psychiatric Institute and Clinic, and is Chief of Comprehensive Recovery Services at Western Psychiatric Institute and Clinic, located in Pittsburgh, Pennsylvania. He was schooled at The Lawrence School, Lovedale, and Christ College, Bangalore, and received his medical training at the Kasturba Medical College, Manipal, all in India. His world-wide training in psychiatry began at the National Institute of Mental Health and Neurosciences, Bangalore, India; followed by the University of Edinburgh (Scotland), Dalhousie University (Halifax, Nova Scotia, Canada) culminating in a NIMH-sponsored clinical research fellowship at the University of Pittsburgh, Pennsylvania; following which he joined the psychiatric faculty at Western Psychiatric Institute and Clinic.

For 25 years, he has conducted clinical trials of antipsychotic and anticonvulsant agents in persons with schizophrenia, schizoaffective or bipolar disorder. In recent years, he has investigated the use of nutraceuticals or herbal-botanical products such as L-Carnosine or Ashwagandha (an extract of *Withania somnifera*) as potential cognition enhancing or anti-inflammatory agents in people with mental illness. For the past decade, he has been investigating how best to aid people with severe mental illnesses to quit smoking. The research studies noted above have been funded by the NIH or foundations such as the Stanley Medical Research Institute or NARSAD or the pharmaceutical industry. He has published the results of his research in several peer-reviewed journals. For the past decade, he has served as Co-Editor in Chief of the *Journal of Bipolar Disorders*. He has direct patient care responsibilities and is involved in the mentoring of junior faculty, psychiatric residents, medical students and other health care professionals.



New Investigator Awardees

Vishesh Agarwal, M.D.

Einstein Medical Center

Elizabeth Ballard, Ph.D.

National Institute of Mental Health

Isabelle Bauer, Ph.D.

University of Texas at Houston

Savita Bhakta, M.D.

VA San Diego Healthcare System

Ram Bishnoi, M.D., M.B.B.S

UTHSCSA

Kailyn Bradley, Ph.D.

Icahn School of Medicine at Mount Sinai

Justin Chen, M.D., M.P.H.

Massachusetts General Hospital &
Harvard Medical School

Stefano Comai, Ph.D.

McGill University, Department of
Psychiatry

Crystal Cooper, Ph.D.

The University of Texas Southwestern
Medical Center, Department of
Psychiatry

Mehdi Farokhnia, M.D.

Section on Clinical
Psychoneuroendocrinology and
Neuropsychopharmacology, Laboratory
of Clinical and Translational Studies,
National Institute on Alcohol Abuse and
Alcoholism and Intramural Research
Program, National Institute on Drug
Abuse, National Institutes of Health

David Goldsmith, M.D.

Emory University School of Medicine,
Department of Psychiatry

Dawn Ionescu, M.D.

Massachusetts General Hospital

Timothy Mariano, M.D., Ph.D.

Alpert Medical School, Brown University

Søren Dinesen Østergaard, M.D., Ph.D.

Department of Clinical Medicine, Aarhus
University

Erica Richards, M.D., Ph.D.

National Institute of Mental Health

Hitoshi Sakurai, M.D.

Department of Neuropsychiatry, Keio
University School of Medicine

Jeff Sanders, M.D., Ph.D.

Emory University School of Medicine
Department of Psychiatry

Diana Simeonova, Dipl.Psych, Ph.D.

Emory University School of Medicine
Department of Psychiatry

Hiroyoshi Takeuchi, M.D., Ph.D.

Centre for Addiction and Mental Health,
University of Toronto

Anvi Vora, M.D.

Bronx VAMC / Mount Sinai School of
Medicine

Kazunari Yoshida, M.D., Ph.D.

Department of Neuropsychiatry, Keio
University School of Medicine

Regulatory Plenary: FDA and EMA Approaches to Innovation in Clinical Trials

Tuesday, June 23, 2015 from 8:30 am – 10:00 am



Maurizio Fava, M.D.
Massachusetts General Hospital

Dr. Maurizio Fava is Director of the Clinical Research Program, Executive Vice Chair of the Department of Psychiatry and Executive Director of the Clinical Trials Network and Institute, Massachusetts General Hospital (MGH), and the Slater Family Professor of Psychiatry at Harvard Medical School.

Dr. Fava is a world leader in the field of depression. He has authored or co-authored more than 700 original articles published in medical journals with international circulation, edited eight books, and published more than 50 chapters and over 500 abstracts. The citation impact of Dr. Fava's work is extremely high, as his articles have been cited more than 40,000 times in the literature, with an h-index of over 100.

Dr. Fava obtained his medical degree from the University of Padova School of Medicine and completed residency training in endocrinology at the same university. He then moved to the United States and completed residency training in psychiatry at the Massachusetts General Hospital. He founded and was Director of the hospital's Depression Clinical and Research Program from 1990 until 2014. In 2007, he also founded and is now the Executive Director of the MGH Psychiatry Clinical Trials Network and Institute (CTNI), the first academic CRO specialized in the coordination of multi-center clinical trials in psychiatry.

Under Dr. Fava's direction, the Depression Clinical and Research Program became one of the most highly regarded depression programs in the country, a model for academic programs that link, in a bi-directional fashion, clinical and research work.

Dr. Fava has been successful in obtaining funding as principal or co-principal investigator from both the National Institutes of Health and other sources for a total of more than \$60,000,000. Dr. Fava's prominence in the field is reflected in his role as the co-principal investigator of STAR*D, the largest research study ever conducted in the area of depression, and of the RAPID Network, the NIMH-funded series of studies of novel, rapidly-acting antidepressant therapies.

Dr. Fava has received several awards during his career and is on the editorial board of five international medical journals. Since 1990, Dr. Fava has also mentored more than 50 trainees who have gone on to become lead investigators in the area of psychiatry. He has developed with Dr. David Schoenfeld a novel design (with over five patents) to address the problem of excessive placebo response in drug trials and to markedly reduce sample size requirements for these trials.



Tiffany Farchione, M.D.
US Food and Drug Administration

Dr. Farchione received her medical degree from Wayne State University in Detroit, Michigan, and completed adult residency and child & adolescent fellowship training at the University of Pittsburgh's Western Psychiatric Institute and Clinic. Dr. Farchione is board certified in both general and child & adolescent psychiatry. Prior to joining FDA in 2010, Dr. Farchione was affiliated with the University of Pittsburgh

Medical Center and was on the faculty of the University of Pittsburgh.

As the Deputy Division Director in the Division of Psychiatry Products at the FDA, Dr. Farchione is involved in the oversight of new drug review for all psychiatric drug development activities conducted under INDs, and the review of all NDAs and supplements for new psychiatric drug claims.



Luca Pani, M.D.
Italian Medicines Agency

Luca Pani, M.D., specialized in Psychiatry, is an expert in Pharmacology and Molecular Biology, and a Fellow of the National Research Council of Italy and currently serves as Director General of the Italian Medicines Agency (AIFA).

Prof. Pani's professional trajectory has touched several areas of expertise from preclinical study to clinical activity as well as R&D of CNS drugs, along with his commitment to teaching and clinical activity, such as: national and international regulatory activities for the European Union; preparation, evaluation and coordination of Research Projects; Strategic Planning and partnerships with national and international Research Groups; participation in international bodies and Advisory Committees.

Dr. Pani is an Italian Member of the Committee for Human Medicine Products (CHMP); Member of the Scientific Advice Working Party (SA-WP); Member of the Working Party on Central Nervous System (WP-CNS); Chair of the European Union Management Board Telematic Committee (EUMBTC); Chair of the European Risk Management Strategy Facilitation Group (ERMS-FG) of the European Medicines Agency (EMA) in London (UK).

Luca Pani is the author of over one hundred scientific publications. Editor and author of several volumes. He has attended more than 1000 conferences, seminars and national and international roundtables as an invited speaker.



Robert Temple, M.D.
US Food and Drug Administration

Dr. Robert Temple has been Deputy Center Director for Clinical Science at FDA's Center for Drug Evaluation and Research since 2009, participating in the direction of the Center's operations. He is also Acting Deputy Director of the Office of Drug Evaluation I (ODE-I). ODE-I is responsible for the regulation of cardio-renal, neuropharmacologic, and psychopharmacologic drug products.

Dr. Temple served as Director, Office of Medical Policy from 1999-2009. The Office of Medical Policy is responsible for regulation of promotion through the Office of Prescription Drug Products (formerly, Division of Drug Marketing, Advertising, and Communication) and for assessing quality of clinical trials.

Dr. Temple has a long-standing interest in the design and conduct of clinical trials and has written extensively on this subject, especially on choice of control group in clinical trials, evaluation of active control and non-inferiority trials, trials to evaluate dose-response, and trials using "enrichment" designs.

Keynote Session: *Changing the Paradigm from Diagnose and Treat to Predict and Preempt*

Wednesday, June 24, 2015 from 8:15 am - 9:45 am



Hussein Manji, M.D.
Johnson & Johnson Pharmaceutical Research & Development

Hussein K. Manji, M.D., FRCP is Global Therapeutic Head for Neuroscience at Janssen Research & Development, LLC, a division of Johnson & Johnson. Previously, he was Chief, Laboratory of Molecular Pathophysiology & Experimental Therapeutics, NIH, and Director of the NIH Mood and Anxiety Disorders Program. Dr. Manji received his B.S. and

M.D. from the University of British Columbia. He completed fellowship training at the NIMH and completed additional training in cellular and molecular biology. His research has focused on investigation of disease-and treatment-induced changes in gene and protein networks that regulate synaptic and neural plasticity. His work has led to investigation of novel therapeutics for patients with refractory neuropsychiatric illnesses. Dr. Manji has also been involved in medical and postgraduate neuroscience education and has published extensively on the molecular and cellular neurobiology of neuropsychiatric disorders and the development of novel therapeutics. Dr. Manji has received numerous distinguished scientific and academic awards, including the NIMH Director's Career Award for Significant Scientific Achievement, and was inducted in to the U.S. Institute of Medicine of the National Academies in 2008. He has served as

Chair of the American College of Neuropsychopharmacology, is a Counselor to the Society of Biological Psychiatry and serves on a variety of editorial boards of scholarly journals. He holds voluntary leadership positions in many organizations devoted to advancement of neuroscience and advocacy for people with neuropsychiatric illnesses. He has been a member of the Howard Hughes Medical Institute and NIH Research Scholars Program Advisory Committee.



**Vaibhav Narayan, Ph.D.
Johnson & Johnson**

Dr. Narayan is currently Head of Neuroscience Integrated Solutions, Informatics and Disease Interception at Janssen Neuroscience. The Neuroscience Therapeutic Area at Janssen is pioneering a more personalized and holistic approach to therapeutic intervention that goes ‘beyond the pill’, to offer data-driven and science-based ‘integrated solutions’ for preventing, diagnosing, treating, and monitoring

CNS diseases. Dr. Narayan’s work is currently focused on utilizing state-of-the-art informatics methods for developing markers for early diagnosis, disease progression, drug response and treatment monitoring in Alzheimer’s and Mood; and to develop novel ‘point-of-need’ tools and technologies for management of adherence and prediction of relapse in patients with Schizophrenia.

Dr. Narayan joined Johnson and Johnson from Eli Lilly and Co., where he headed the Discovery and Biomedical Informatics group to enable Lilly’s translational, biomarker, and tailored therapeutics strategies. Prior to Lilly, Vaibhav held multiple leadership roles in various small to mid-size biotech companies such as Celera Genomics, CuraGen Corporation and Vertex pharmaceuticals during which time he participated in multiple landmark ‘Big Biology’ projects, including sequencing, assembly and analysis of the human genome (Human Genome Project) and elucidation of the first complete protein-protein interaction map of a whole organism.

Dr. Narayan obtained his Ph.D. from Yale University jointly from the Departments of Chemistry, and Molecular Biophysics & Biochemistry in 1998, and an Executive MBA from Kellogg School of Management, Northwestern University in 2009.



Geraldine Dawson, Ph.D.
Duke University

Geraldine Dawson is Professor, the Departments of Psychiatry and Behavioral Sciences, Pediatrics, and Psychology, and Neuroscience and Director of the Duke Center for Autism and Brain Development at Duke University, North Carolina. She is also Professor of Psychology Emerita at the University of Washington and Adjunct Professor of Psychiatry at Columbia University. Dawson is President of the International Society for Autism Research. She served as a member of the NIH

Interagency Autism Coordinating Committee (IACC) which develops the federal strategic plan for autism research, services, and policy.

Dr. Dawson is a licensed practicing clinical psychologist and scientist, having published more than 225 articles and 10 books on early detection and treatment of autism and brain development. Her scientific research was recognized by the National Institutes of Health as a Top Advance in Autism Research in 2007, 2008, 2009, 2010, 2012, and 2013. Dawson's laboratory pioneered the use of electrophysiological methods to study very early brain function in young children with autism and conducted research that first established that autism symptoms were present in the first year of life. With Sally Rogers, she developed the Early Start Denver Model, an empirically-validated comprehensive intervention for toddlers with autism. Her research demonstrating that early intervention can normalize brain activity in children with autism was recognized by *TIME* magazine as one of the top 10 medical breakthroughs of 2012.

From 2008-2013, Dr. Dawson was Research Professor of Psychiatry at the University of North Carolina, Chapel Hill and served as the first Chief Science Officer for Autism Speaks, the largest autism science and advocacy organization, where she oversaw \$25-30 million of annual research funding aimed at a diverse portfolio from basic to applied science and advocated for state and federal policy and legislative efforts aimed at increasing autism research funding and improving access and quality of services for people with autism. From 1985-2008, Dawson was Professor of Psychology at the University of Washington. There, she was Founding Director of the University of Washington Autism Center where she directed three consecutive interdisciplinary NIH Autism Center of Excellence research programs on genetics, neuroimaging, early diagnosis, and treatment, and oversaw the University of Washington Autism Treatment Center, which provides interdisciplinary clinical services for individuals with autism from infancy through young adulthood.

Dr. Dawson is a Fellow of the American Psychological Society and American Psychological Association, and on editorial boards of four scientific journals. Dawson's awards include a Lifetime Achievement Award from the Association for Psychological Science for outstanding contributions to the area of applied psychological research that addresses a critical problem in society at large, Autism Society of America Awards for Valuable Service and Research Contributions, Cure Autism Now Hero Award, Geoffrey Beene Rock Star of Science Award, among others. A strong advocate for families, Dawson has testified before the United States Congress three times to support autism legislation. She received a Ph.D. in Developmental and Child Clinical Psychology from the University of Washington and completed a clinical internship at the UCLA Neuropsychiatric Institute.



John Kane, M.D.
The Zucker Hillside Hospital

John M. Kane, M.D. is Senior Vice President of Behavioral Health Services for the North Shore-Long Island Jewish Health System and Professor and Chairman of Psychiatry at the Hofstra North Shore-LIJ School of Medicine. He currently directs the NIMH-funded Advanced Center for Interventions and Services Research in Schizophrenia at The Zucker Hillside Hospital. He has been a member of the Board of Scientific

Counselors for NIMH. He has served as President of the Schizophrenia International Research Society and the American Society of Clinical Psychopharmacology. He has chaired the NIMH Psychopathology and Psychobiology Review Committee as well as the Psychopharmacologic Drugs Advisory Committee of the Food and Drug Administration. Dr. Kane has authored or coauthored over four hundred publications in peer reviewed journals.

Dr. Kane is a recipient of the Arthur P. Noyes Award in Schizophrenia, the NAPPH Presidential Award for Research, the American Psychiatric Association Foundations' Fund Prize for Research, the APA's Kempf Fund Award for Research Development in Psychobiological Psychiatry, the Lieber Prize for Outstanding Research in Schizophrenia, the Heinz E. Lehmann Research Award from New York State, and the Dean Award from the American College of Psychiatrists.

Dr. Kane received his B.A. from Cornell University and his M.D. from the New York University School of Medicine.



Ellen Frank, Ph.D.
University of Pittsburgh School of Medicine

For more than 25 years Dr. Frank has been studying interventions for mood disorders and the pathophysiology underlying response to those interventions. Her 1990 study of maintenance therapies in recurrent unipolar depression is now considered a classic in the field. Under a MERIT Award from the NIMH for MH029618, she and her colleagues demonstrated the efficacy of interpersonal and social rhythm

therapy (IPSRT), a psychotherapy for bipolar disorder that focuses on instantiating highly regular social and sleep/wake routines as a means of enhancing circadian integrity and on addressing problems in patients' interpersonal relationships and social roles. Together with Tina Goldstein, she recently completed a study of IPSRT as a preventative treatment for adolescents at-risk for bipolar disorder. She is currently working with colleagues in the Information Science department at Cornell University to develop MoodRhythm, a mobile app that brings to core of IPSRT to patients' mobile phones.

Institute Directors Plenary**Wednesday, June 24, 2015 from 10:15 am – 11:45 am****Michael Thase, M.D.****Perelman School of Medicine at the University of Pennsylvania**

Michael E. Thase, M.D., joined the faculty of the University of Pennsylvania School of Medicine in January 2007, as Professor of Psychiatry after more than 27 years at the University of Pittsburgh Medical Center and the Western Psychiatric Institute and Clinic. Dr. Thase's research focuses on the assessment and treatment of mood disorders, including studies of the differential therapeutics of both depression and bipolar affective disorder. A 1979 graduate of the Ohio State University College of Medicine, Dr. Thase is a Distinguished Fellow of the American Psychiatric Association, a Founding Fellow of the Academy of Cognitive Therapy, a member of the Board of Directors for the American Society of Clinical Psychopharmacology, and Vice Chairman of the Scientific Advisory Board of the National Depression and Bipolar Support Alliance. Dr. Thase has been elected to the membership of the American College of Psychiatrists and the American College of Neuropsychopharmacology. Dr. Thase has authored or co-authored more than 500 scientific articles and book chapters, as well as 15 books.

**Steve Zalcman, M.D.****National Institute of Mental Health/NIH**

Steven Zalcman is the Chief of the Clinical Neuroscience Research Branch in the National Institute of Mental Health's (NIMH) Division of Translational Research at NIH. In that role he is responsible for a research portfolio involving human and animal studies at the molecular, cellular, and systems level of brain function designed to elucidate the pathophysiology of mental disorders and to translate these findings to clinical diagnosis, treatment, and prevention strategies. The Branch also funds the Silvio O. Conte Centers for the Neuroscience of Mental Disorders which support hypothesis-driven, interdisciplinary research centers, each of which brings the best scientific talent and resources from multiple disciplines and perspectives to bear on specific questions directly relevant to complex mental disorders.

Dr. Zalcman received his medical degree from Washington University School of Medicine in St. Louis (1973) where he also completed an internship in internal medicine and a residency in psychiatry prior to coming to NIMH's intramural research program. He served as a postdoctoral fellow and research physician in the Laboratory of Clinical Psychopharmacology prior to assuming a position in NIMH's extramural research programs.



**Phil Skolnick, Ph.D., D.Sc. (hon.)
National Institute on Drug Abuse**

Phil Skolnick is the Director, Division of Pharmacotherapies and Medical Consequences of Drug Abuse at the National Institute on Drug Abuse, NIH. Dr. Skolnick served as Chief Scientific Officer (2001-2009) and President (2007-2009) of DOV Pharmaceutical, Inc. He was also Research Professor of Psychiatry (2001-2009) and a member of the Center of Excellence on Drug Addiction at New York University-

Langone Medical Center. Dr. Skolnick was a Lilly Research Fellow (Neuroscience) at Lilly Research Laboratories (1997-2000). Prior to this, he was a Senior Investigator and Chief, Laboratory of Neuroscience, at the NIH intramural research program (1986-1997). Dr. Skolnick has also served as a Research Professor of Psychiatry at the Uniformed Services University of the Health Sciences, Adjunct Professor of Anesthesiology at Johns Hopkins University, and Adjunct Professor of Pharmacology and Toxicology at Indiana University School of Medicine. He received a Ph.D. from the Department of Pharmacology, George Washington University School of Medicine (1972), and served as a Staff Fellow and Senior Staff Fellow at the NIH under Dr. John W. Daly (1972-1977).

His awards and honors include the Experimental Therapeutics Prize from the American Society for Pharmacology and Experimental Therapeutics, an Anna Monika Prize, and the A.E. Bennett Award in Biological Psychiatry. He has twice been awarded the Doctor of Science, honoris causa. Dr. Skolnick has co-authored more than 500 articles and currently serves on the editorial advisory board of seven journals. He is currently an editor of *Current Protocols in Neuroscience*, and has also edited six books. The Institute of Scientific Information (ISI) has acknowledged his contributions by naming him to the elite group of "Highly Cited" authors. Dr. Skolnick currently serves as a member of the Research Advisory Board of the George Washington University, a member of the Senior Advisory Committee to the NCI Experimental Therapeutics (NExT) Program, and a member of the Steering Committee of the American Society of Clinical Psychopharmacology.



David Shurtleff, Ph.D.
National Center for Complementary and Integrative Health

David Shurtleff, Ph.D., is Deputy Director of the National Center for Complementary and Integrative Health (NCCIH; Formerly NCCAM) performing a wide range of activities supporting the Director and the NCCIH organization. A component of the National Institutes of Health (NIH), NCCIH defines, through scientific investigation, the usefulness and

safety of complementary and integrative health interventions.

Dr. Shurtleff began his NIH career in 1995 at the National Institute on Drug Abuse (NIDA). In 1997, he was appointed Deputy Director of NIDA's Division of Neuroscience and Behavioral Research. From 2001 to 2010, Dr. Shurtleff served as the Director of the Division of Basic Neuroscience and Behavioral Research, and from January 2011 to June 2013, he served as the Acting Deputy Director of NIDA before joining NCCIH.

Prior to coming to NIH, Dr. Shurtleff was a research psychologist at the Naval Medical Research Institute (NMRI) in Bethesda, Maryland, where he conducted basic behavioral, electrophysiological, and field research on a variety of issues related to cognitive performance, environmental stress, and peripheral neuropathy. Prior to joining NMRI, he served as a research fellow at the Walter Reed Army Institute of Research in the Department of Medical Neurosciences.

He has received various honors and awards including several NIH Director's Awards. One of these awards recognized his outstanding contributions to the development and advancement of diverse programs in basic neuroscience and behavioral research.



Rajesh Ranganathan, Ph.D.
National Institutes for Neurological Disorders and Stroke/National Institutes of Health

Dr. Rajesh Ranganathan is currently the Director of the Office of Translational Research (OTR) at National Institutes for Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH) and has been in this role since January 2012. The OTR currently has five funding programs that aim to provide a breadth of opportunities for academic

investigators and small businesses to engage in the spectrum of work, beginning with assay development through to initial test of clinical candidate in human trials. The emerging priorities of the office are to ensure that therapeutic development is partnered with the development of mechanistic biomarkers to facilitate deeper understanding of the mechanism of action of the therapeutic candidate. Additionally, there will be emphasis going forward on engaging other stakeholders, such as pharma, biotech, venture capital, and patient organizations to ensure that projects in the office's portfolio have been appropriately de-risked to ensure downstream investments, which will

accelerate getting the much-needed therapies to patients suffering from neurological disorders.

Previously, Dr. Ranganathan served in the NIH Office of the Director beginning in November 2010, as the Senior Advisor to the NIH Director for Translational Medicine. Prior to that, he spent more than 7 years at the Novartis Institutes for BioMedical Research, Inc. where he was a Director in the scientific strategy and portfolio management group and also founded and led a Global Office of Scientific Education for the Institutes. Dr. Ranganathan received his bachelor's degrees in biology and chemistry from Amherst College, performed his doctoral training with Dr. H. Robert Horvitz at MIT in *C. elegans* neurobiology, and his postdoctoral training with Dr. Linda Buck at Harvard Medical School and the Fred Hutchinson Cancer Research Center in the area of mammalian sensory regulation.



Richard Nakaruma, M.D. **Center for Scientific Review**

Dr. Richard K. Nakamura is the Director of the Center for Scientific Review. In that capacity, he leads the review of grant applications of the National Institutes of Health. Dr. Nakamura received his Bachelor of Arts in Psychology from Earlham College and his Ph.D. in psychology from State University of New York (Stony Brook, NY). He was with the National Institute of Mental Health from 1976 to 2011. In

2001, he received the NIH-Asian/Pacific American Organization (APAO) Outstanding Achievement Award for Administrative Work. In 2002, Dr. Nakamura was elected by the American Association for the Advancement of Science (AAAS) to the status of AAAS Fellow. Also in 2002, Dr. Nakamura was awarded the Presidential Rank Award for outstanding leadership. In 2004 and 2005 respectively, he received leadership awards from the Federation of Behavioral Psychological and Cognitive Sciences, and from the International Society for Behavioral Neuroscience. In 2009, he was awarded the NIH Director's Award for Outstanding Administration.

Regulatory Wrap-Up**Thursday, June 25, 2015 from 10:15 am – 11:45 am****Maurizio Fava, M.D.****Massachusetts General Hospital***See previous bio***Tiffany Farchione, M.D.****US Food and Drug Administration***See previous bio***Luca Pani, M.D.****Italian Medicines Agency***See previous bio*

Steering Committee Chairs



Husseini Manji, M.D., FRCPC



Michael E. Thase, M.D.

Program Chairs




Alan Gelenberg, M.D.



Holly A. Swartz, M.D.

New Investigator Award Program Chairs



Mark H. Rapaport, M.D.



Christopher Sarampote, Ph.D.

Steering Committee Members

- ★ Lori Davis, M.D.
Veterans Affairs Medical Center

- Bryan L. Dirks, M.D.
Shire Pharmaceuticals

- Maurizio Fava, M.D.
Massachusetts General Hospital (ASCP Board Member)

- James H. Kocsis, M.D.
Weill-Cornell Medical College

- David J. Kupfer, M.D.
University of Pittsburgh School of Medicine

- Thomas P. Laughren, M.D.
Food and Drug Administration

- Raye Litten, Ph.D.
National Institute of Alcohol Abuse and Alcoholism

- ★ Anil K. Malhotra, M.D.
Hofstra NS-LIJ School of Medicine
The Zucker Hillside Hospital

- Husseini K. Manji, M.D., F.R.C.P.C.
Johnson & Johnson Pharmaceutical Research & Development

- Steve Marder, M.D.
University of California Los Angeles

- David Michelson, M.D.
Merck & Company, Inc.

- Andrew A. Nierenberg, M.D.
Massachusetts General Hospital

- William Z. Potter, M.D., Ph.D.
National Institute of Health

- Stephanie O'Malley, Ph.D.
Yale University School of Medicine

- ▲ Mark H. Rapaport, M.D.
Emory University School of Medicine (ASCP Board Member)

★ **New Investigator Alumni** ▲ **Representing ASCP CME Committee**

Steering Committee Members (continued)

Nina R. Schooler, Ph.D.
State University of New York, Downstate Medical Center

Philip Skolnick, Ph.D., D.Sc.
National Institute on Drug Abuse

Holly Swartz, M.D.
University of Pittsburgh School of Medicine

Madhukar Trivedi, M.D.
UT Southwestern/Bass Center

Michael Thase, M.D.
University of Pennsylvania School of Medicine (ASCP Board Member)

Benedetto Vitiello, M.D.
National Institute of Mental Health

- ★ Carlos A. Zarate, M.D.
National Institute of Mental Health

Program Committee

Leslie Citrome, M.D., M.P.H.
New York Medical College (ASCP Board Member)

Lawrence Cohen, Pharm.D.
UNT Health Science Center/ UNT System College of Pharmacy

- ★ Christoph U. Correll, M.D.
The Zucker Hillside Hospital (ASCP Board Member)

Thilo Deckersbach, Ph.D.
Massachusetts General Hospital

- ★ Eden Evins, M.D.
Harvard Medical School

- ★ Tiffany R. Farchione, M.D.
US Food and Drug Administration

Maurizio Fava, M.D.
Massachusetts General Hospital (ASCP Board Member)

Bradley Gaynes, M.D.
University of North Carolina School of Medicine

★ **New Investigator Alumni** ▲ **Representing ASCP CME Committee**

Program Committee (continued)

Alan Gelenberg, M.D. (Co-Chair)
The Journal of Clinical Psychiatry

Ahmad Hameed, M.D.
Penn State College of Medicine

Richard Keefe, Ph.D.
Duke University Medical Center

Terence Ketter, M.D.
Stanford University School of Medicine

Thomas P. Laughren, M.D.
US Food and Drug Administration

★ Anil Malhotra, M.D.
Hofstra NS-LIJ School of Medicine, The Zucker Hillside Hospital

Stephen Marder, M.D.
Semel Institute, UCLA

▲ Craig Nelson, M.D.
University of California San Francisco

★ Katharine Phillips, M.D.
Rhode Island Hospital/Brown University

Jerrold Rosenbaum, M.D.
Massachusetts General Hospital

Martha Sajatovic, M.D.
University Hospitals Case Medical Center

Bruce Saltz, M.D., P.A.
Mental Health Advocates, Inc.

★ Erika Saunders, M.D.
Penn State MS, Hershey Medical Center

Richard Shelton, M.D.
University of Alabama at Birmingham

★ Holly A. Swartz, M.D. (Co-Chair)
University of Pittsburgh School of Medicine

Benedetto Vitiello, M.D.
National Institute of Mental Health

★ **New Investigator Alumni** ▲ **Representing ASCP CME Committee**

Program Committee (continued)

- ★ Kimberly Yonkers, M.D.
Yale School of Medicine
- ★ Carlos A. Zarate, M.D.
National Institute of Mental Health

New Investigator Award Program Committee

- Mark Bunker, Pharm.D.
Cyberonics, Inc.
- ★ Christoph U. Correll, M.D.
The Zucker Hillside Hospital
- ★ Lori Davis, M.D.
Veterans Affairs Medical Center
- ★ Tiffany Farchione, M.D.
US Food and Drug Administration
- Lindsey Grandison, Ph.D.
National Institute on Alcohol Abuse and Alcoholism
- Bruce Kinon, M.D.
Lundbeck
- Ivan Montoya, M.D., M.P.H.
National Institute on Drug Abuse
- ★ Katharine Phillips, M.D.
Rhode Island Hospital/Brown University
- ▲ Mark H. Rapaport, M.D. (Co-Chair)
Emory University School of Medicine (ASCP Board Member)
- Christopher Sarampote, Ph.D. (Co-Chair)
National Institute on Mental Health
- Nina R. Schooler, Ph.D.
State University of New York, Downstate Medical Center
- ★ Holly A. Swartz, M.D.
University of Pittsburgh School of Medicine

★ New Investigator Alumni ▲ Representing ASCP CME Committee

ASCP Officers and Board

- Maurizio Fava, M.D. – ASCP President
Massachusetts General Hospital
- ▲ Mark H. Rapaport, M.D. – ASCP Treasurer
Emory University School of Medicine
- Leslie Citrome, M.D., M.P.H.
New York Medical College
- ★ Christoph U. Correll, M.D.
The Zucker Hillside Hospital
- ★ Kristina Deligiannidis, M.D.
University of Massachusetts Medical School
- ▲ Marlene Freeman, M.D.
Massachusetts General Hospital
- Alan Gelenberg, M.D.
The Journal of Clinical Psychiatry
- Ira Glick, M.D.
Stanford University School of Medicine
- ▲ Joseph Goldberg, M.D.
Mount Sinai School of Medicine
- ▲ John Kane, M.D.
The Zucker Hillside Hospital
- Arif Khan, M.D.
Duke University School of Medicine
- John Newcomer, M.D.
Florida Atlantic University
- Michael Thase, M.D.
University of Pennsylvania
- Karen Wagner, M.D., Ph.D.
University of Texas Medical Branch
- Sidney Zisook, M.D.
University of California, San Diego

★ New Investigator Alumni ▲ Representing ASCP CME Committee

Meeting Services

Registration Desk Hours:

Sunday	10:00 am – 5:00 pm
Monday	7:30 am – 6:30 pm
Tuesday	7:30 am – 6:45 pm
Wednesday	7:30 am – 6:00 pm
Thursday	7:30 am – 12:00 pm

*The registration/meeting information desk is located in the Rotunda on the Second Level.

The ASCP Speaker Ready Room is open on the below dates and times for presenters to upload slides. The meeting organizers ask that all speakers upload their slides 24 hours prior to their scheduled presentation time.

The Speaker Ready Room is located in the Sundial meeting room, located on the Third Level.

Sunday	12:00 pm – 5:00 pm
Monday	8:00 am – 6:00 pm
Tuesday – Wednesday	7:30 am – 6:30 pm
Thursday	7:30 am – 12:00 pm

ASCP Wi-Fi

Network: ascp2015

Access PIN: ascp2015

Americans with Disabilities Act - It is the policy of ASCP not to discriminate against any person on the basis of disabilities. If you feel you need services or auxiliary aids mentioned in this act in order to fully participate in this continuing education activity, please call the Executive Office at 615-649-3085 or send an email to info@ascpp.org.

Discounts – All ASCP Annual Meeting attendees who booked their room at the Loews Miami Beach Hotel through the ASCP meeting website will have the following resort amenities.

- Complimentary internet in the guest rooms.
- Fitness Center admittance
- Daily newspaper App
- In-room coffee and tea

Abstracts – All abstracts can be viewed online at www.ASCPMeeting.org.

ASCP | Meeting Announcements

Continuing Education Credits

Disclosures are available for all ASCP Annual Meeting presenters online at www.ASCPMeeting.org.

Continuing Education Credits are available for physicians, pharmacists, psychologists and social workers. Applications for credit must be completed online with the meeting evaluation survey. The survey may be completed after the conference at www.ASCPMeeting.org. ***Surveys for continuing education credit must be submitted no later than July 27, 2015.*** There is a \$40.00 administrative fee for CME/CE applications. It is the policy of the ASCP to require disclosure of financial relationships from individuals in a position to control the content of a CME activity; to identify and resolve conflicts of interest related to those relationships; and to make disclosure information available to the audience prior to the CME activity. Presenters are required to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentations.

Physicians



ASCP
AMERICAN SOCIETY OF
CLINICAL PSYCHOPHARMACOLOGY

The American Society for Clinical Psychopharmacology (ASCP) designates this live meeting for a maximum of 25 *AMA PRA Category*

1 Credit(s)[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists



USF Health is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This knowledge-based program has been approved for 25 contact hours. Universal program number is as follows:

0230-9999-15-008-L04-P.

To receive continuing education credit, a pharmacist must attend the accredited sessions, actively participate in questions and answers and must return the program evaluation instrument. In order to receive full credit, registrants must arrive no later than 10 minutes after the start of the meeting and must attend the entire meeting.

Psychologists



USF Health is approved by the American Psychological Association to sponsor continuing education for psychologists. USF Health maintains responsibility for this program and its content. This activity has been approved for 25 CE credits. Full attendance of the live activity is required. Partial credit will not be awarded.

Social Workers



USF Health is an approved provider of continuing education credits for clinical social work, marriage and family therapy, and mental health counseling. This program has been reviewed and approved for 30 credit hours, 50-minute contact hours.

All participants who request continuing education credits by July 27, 2015, should expect to receive their statement of credits via email in late August.

The Meeting Evaluation Survey will be available at www.ASCPMeeting.org. We encourage all registrants to complete the evaluation. Attendees requesting CME or CE credits must complete the survey in order to obtain credits. There is a \$40.00 administrative fee for CME/CE applications. Your candid input on the 2015 meeting is appreciated as we strive to improve the meeting each year.

ASCP Meeting Support – The 2015 ASCP Annual Meeting receives no corporate funding.

Special thanks to the ASCP New Investigator Program Supporter:
Sunovion Pharmaceuticals, Inc.

2016 ASCP Annual Meeting – Save the Date



Fairmont
SCOTTSDALE PRINCESS



The 2016 ASCP Annual Meeting will take place May 30 – June 2, 2016 at the Fairmont Princess Hotel in Scottsdale, Arizona. Details regarding abstract submission for the 2016 Meeting will be released in September, 2015.

[illegible]

AT-A-GLANCE

Sunday, June 21, 2015

8:30am – 4:15pm	New Investigator Workshop (<u>Invitation Only</u>) Cowrie 2
10:00am – 5:00pm	Registration Open Rotunda
12:00pm – 1:15pm	*Latin American Psychopharmacology Update: Innovative Treatments in Psychiatry Poinciana 1-2
1:15pm – 2:30pm	*Latin American Psychopharmacology Update: New Pharmacological Targets: From Pre-clinical Models to Patient Care Poinciana 1-2
2:30pm – 2:45pm	Break Americana Foyer
2:45pm – 4:00pm	*Latin American Psychopharmacology Update: Developing New Targets for Pharmacological Interventions Poinciana 1-2

**of special interest to clinicians*

[illegible]

FULL SCHEDULE

Sunday, June 21, 2015

8:30am – 4:15pm

New Investigator Workshop (Invitation Only)

Cowrie 2

Co-Chairs: Mark H. Rapaport, M.D., Emory University School of Medicine
Christopher Sarampote, Ph.D., National Institute of Mental Health

The ASCP Annual Meeting offers a special program for New Investigators in an effort to promote the education and training of junior investigators in psychopharmacology. Established investigators were asked to nominate individuals who may be interested in a research career in psychopharmacology for this special program. These nominees submitted an abstract describing their current research or area of research interest, a letter of recommendation from their chair or mentor, a career statement and a curriculum vitae. The selection of awardees was based upon the scientific merit of the abstract, the level of training of the nominee and a committee of internal and external reviewers' assessment of the relative value of the specialized program to each applicant at this time in his/her career. The awardees will participate in this special educational workshop and present their posters during the scheduled poster sessions. In addition, they will receive a travel expense award and a certificate acknowledging their participation in the program at an award ceremony on Monday evening, June 22, 2015. This year's 21 New Investigator awardees are indicated with a ribbon in the poster section of this program.

Faculty

Joseph Blader, M.D.
University of Texas Health Science
Center at San Antonio

Mark Bunker, Pharm.D.
Cyberonics, Inc.

Christoph U. Correll, M.D.
The Zucker Hillside Hospital

Lori Davis, M.D.
Veterans Affairs Medical Center

Lindsey Grandison, Ph.D.
National Institute on Alcohol Abuse
and Alcoholism

Bruce Kinon, M.D.
Eli Lilly & Company

Nina R. Schooler, Ph.D.
State University of New York

Holly Swartz, M.D.
University of Pittsburgh School of
Medicine

Tiffany Farchione, M.D.
Food and Drug Administration

Ivan Montoya, M.D., M.P.H.
National Institute on Drug Abuse

Katharine Phillips, M.D.
Rhode Island Hospital/Brown
University

10:00am – 5:00pm

Registration Open
Rotunda

12:00pm – 1:15pm

***Latin American Psychopharmacology Update:
Innovative Treatments in Psychiatry**
Poinciana 1-2

Chair: Flavio Kapczinski, The University of Texas Health Science Center at Houston

Discussant: Clarissa Gama, UFRGS, HCPA, Porto Alegre, Brazil

12:00pm – 12:05pm

Introduction

12:05pm – 12:20pm

Rescuing Late-stage Bipolar Patients with the Use of Clozapine: Evidence and Clinical Experience
Clarissa Gama, UFRGS, HCPA, Porto Alegre, Brazil

12:20pm – 12:40pm

Sodium Nitroprusside as a Fast-acting Antipsychotic Agent
Jamie Hallak, University of São Paulo

12:40pm – 1:00pm

Deep Brain Stimulation: New Opportunities in Neuropsychiatry
Roger Walz, Universidade Federal de Santa Catarina

1:00pm – 1:15pm

Discussion

1:15pm – 2:30pm

***Latin American Psychopharmacology Update:
New Pharmacological Targets: From Pre-clinical Models to Patient Care**
Poinciana 1-2

Chair: Marco Romano-Silva, Universidade Federal de Minas Gerais

Discussant: Flavio Kapczinski, University of Texas Health Science Center at Houston

1:15pm – 1:20pm

Introduction

1:20pm – 1:35pm

Neurochemical Mechanisms Underlying Ketamine Antidepressant Effect
João de Quevedo, University of Texas Health Science Center at Houston

**of special interest to clinicians*

**1:15pm – 2:30pm
(continued)**

***Latin American Psychopharmacology Update:
New Pharmacological Targets: From Pre-clinical
Models to Patient Care**
Poinciana 1-2

1:35pm – 1:50pm

**Biological Markers in Mood Disorders in Elderly
Patients**

Breno Satler Diniz, Federal University of Minas Gerais

1:50pm – 2:05pm

**Memantine as an Adjunctive Treatment in
Schizophrenia**

Clarissa Gama, UFRGS, HCPA, Porto Alegre, Brazil

2:05pm – 2:30pm

Discussion

2:30pm – 2:45pm

Break

Americana Foyer

2:45pm – 4:00pm

***Latin American Psychopharmacology Update:
Developing New Targets for Pharmacological
Interventions**
Poinciana 1-2

Chair: Flavio Kapczinski, University of Texas Health Science Center at Houston

Discussant: João de Quevedo, University of Texas Health Science Center at Houston

2:45pm – 2:50pm

Introduction

2:50pm – 3:05pm

**Neuro-inflammation in Psychiatric Disorders:
Promises and Evidence**

Antonio Teixeira, Universidade Federal de Minas
Gerais

3:05pm – 3:20pm

Genetic Determinants of Drug Response

Rodrigo Nicolato, UFMG

3:20pm – 3:35pm

**Neuroprogression: From Conceptual Development
to Pharmacological Interventions**

Flavio Kapczinski, University of Texas Health Science
Center at Houston

3:35pm – 4:00pm

Discussion

**of special interest to clinicians*

[illegible]

AT-A-GLANCE

Monday, June 22, 2015

- 7:30am – 6:30pm **Registration Open**
- 7:30am – 8:30am **New Investigator Awardee Breakfast Roundtable (Invitation only)**
Neptune
- 8:30am – 9:00am **Conference Opening**
Americana Ballroom - Salon 3
- 9:00am – 10:30am **Panel Sessions**

Clinical Research Subject Registries: Past Experience and Future Directions	*Managing Complicated Attention Deficit Hyperactivity Disorder with Comorbid Depressive and Anxiety Disorders	*From Agitation to Aggression: Pharmacotherapy and Other Interventions - Sequences, Combinations, and Targets	*Update: Outcomes of Recent NIMH Multisite RCTs in Geriatric Mood Disorders
Location: Poinciana 1-2	Location: Poinciana 3-4	Location: Salon 1 Americana Ballroom	Location: Salon 2 Americana Ballroom

- 10:30am – 10:45am **Break**
Americana Foyer

- 10:45am – 12:15pm **Panel Sessions**

Translational Targets for Stimulant Addiction	New Frontiers in Measurement: The Revolution Will Be Patient-centered	*Defining Treatment Targets Across the Depression Spectrum	The Challenges of Social Connectedness for Adolescents with Autism Spectrum Disorder: Implications for Research and Intervention
Location: Poinciana 1-2	Location: Poinciana 3-4	Location: Salon 1 Americana Ballroom	Location: Salon 2 Americana Ballroom

**of special interest to clinicians*

12:15pm – 2:00pm

Lunch On Own

2:00pm – 4:00pm

***Pharmaceutical Pipeline Presentations**

Salon 3 – Americana Ballroom

4:00pm – 4:15pm

Break

Americana Foyer

4:15pm – 5:30pm

Special Session: Nomenclature Project

Salon 3 – Americana Ballroom

6:15pm – 7:45pm

**New Investigators' Award Ceremony & Reception
(Invitation only)**

Cowrie 2

FULL SCHEDULE

Monday, June 22, 2015

7:30am – 6:30pm	Registration Open <i>Rotunda</i>
7:30am – 8:30am	New Investigator Awardee Breakfast Roundtable (Invitation only) <i>Neptune</i>
8:30am – 9:00am	Conference Opening <i>Salon 3 - Americana Ballroom</i>

Panel Sessions

9:00am – 10:30am	Clinical Research Subject Registries: Past Experience and Future Directions <i>Poinciana 1-2</i>
------------------	--

Chair: Kerri Weingard, Verified Clinical Trials

Discussant: Gary Zammit, Clinilabs, Inc.

9:00am – 9:10am	Introduction
9:10am – 9:30am	Redundancy or Integration: The Future of Subject Registries? Thomas Shiovitz, California Neuroscience Research
9:30am – 9:50am	The Duplicate and Professional Subject Problem and Proposed Solutions Jonathan Rabinowitz, Bar-Ilan University
9:50am – 10:10am	Verified Clinical Trials, Dupcheck and CTSDatabase: Currently Available Registry Solutions to Prevent Duplicate Enrollment Mitchell Efros, Verified Clinical Trials
10:10am – 10:30am	Discussion

9:00am – 10:30am

***From Agitation to Aggression: Pharmacotherapy and Other Interventions - Sequences, Combinations, and Targets**
Salon 1 – Americana Ballroom

Chair: Leslie Citrome, New York Medical College

Discussant: Glenn Currier, University of Rochester Medical Center

9:00am – 9:10am

Introduction

9:10am – 9:30am

Understanding the Psychiatric Pain and Distress Associated with Agitation - Evaluation and Assessment of the Agitated Patient Using the Project Beta Guidelines

Scott Zeller, Alameda Health System

9:30am – 9:50am

Assuaging Agitation: Ingest, Inject or Inhale?

Michael Allen, University of Colorado School of Medicine

9:50am – 10:10am

From Pharmacoepidemiological Studies and Post Hoc Analyses to Randomized Controlled Trials: Preventing Aggressive Episodes

Leslie Citrome, New York Medical College

10:10am – 10:30am

Discussion

9:00am – 10:30am

***Managing Complicated Attention Deficit Hyperactivity Disorder with Comorbid Depressive and Anxiety Disorders**
Poinciana 3-4

Chair: Martin Katzman, START Clinic for Mood and Anxiety Disorders

Discussant: Angelo Fallu, Woodward Clinic

9:00am – 9:10am

Introduction

9:10am – 9:30am

Pharmacotherapeutic Treatment Strategies for Patients with Attention Deficit Hyperactivity Disorder and Comorbid Depressive and Anxiety Disorders

Larry Klassen, START Clinic for Mood and Anxiety Disorders

**of special interest to clinicians*

**9:00am – 10:30am
(continued)** ***Managing Complicated Attention Deficit Hyperactivity Disorder with Comorbid Depressive and Anxiety Disorders**
Poinciana 3-4

9:30am – 9:50am **Challenges in the Detection and Diagnosis of Attention Deficit Hyperactivity Disorder in the Presence of Comorbid Depressive and Anxiety Disorders**
Irvin Epstein, START Clinic for Mood and Anxiety Disorders

9:50am – 10:10am **Understanding the Neurobiology of Attention Deficit Hyperactivity Disorder and Comorbid Depression and Anxiety**
Martin Katzman, START Clinic for Mood and Anxiety Disorders

10:10am – 10:30am **Discussion**

9:00am – 10:30am ***Update: Outcomes of Recent NIMH Multisite RCTs in Geriatric Mood Disorders**
Salon 2 – Americana Ballroom

Chair & Discussant: Charles Reynolds, University of Pittsburgh School of Medicine Department of Psychiatry

9:00am – 9:10am **Introduction**

9:10am – 9:30am **Lithium and Divalproex in the Treatment of Mania in Older Patients with Bipolar Disorder - A Randomized Clinical Trial**
Robert Young, Weill Cornell Medical College

9:30am – 9:50am **That National Institute of Mental Health (NIMH) Studies of the Acute and Continuation Pharmacotherapy of Psychotic Depression (STOP Pd I and II)**
Barnett Meyers, Weill Cornell Medical College

9:50am – 10:10am **Getting to Remission in Late-life Depression: Recent Results and New Directions**
Jordan Karp, University of Pittsburgh

10:10am – 10:30am **Discussion**

**of special interest to clinicians*

10:30am – 10:45am **Break**
Americana Foyer

Panel Sessions

10:45am – 12:15pm **Translational Targets for Stimulant Addiction**
Poinciana 1-2

Chair: Ivan Montoya, DHHS/National Institute on Drug Abuse

Discussant: Phil Skolnick, National Institute on Drug Abuse/NIH/DHHS

10:45am – 10:55am **Introduction**

10:55am – 11:15am **Using X-Ray Structures of the Orexin Receptors to Design New Drugs for the Treatment of Cocaine Addiction**
 Fiona Marshall, Heptares Therapeutics, Ltd.

11:15am – 11:35am **Integrating Serotonin 5-HT_{2C} Receptor Ligands into Therapeutics for Cocaine Use Disorder**
 Kathryn Cunningham, University of Texas Medical Branch

11:35am – 11:55am **Genetically Engineered Butyrylcholinesterase for the Treatment of Cocaine Addiction: Results of PH2 Clinical Study**
 Rom Eliaz, Teva Pharmaceuticals

11:55am – 12:15pm **Discussion**

10:45am – 12:15pm **New Frontiers in Measurement: The Revolution will be Patient-centered**
Poinciana 3-4

Chair: Mark Opler, ProPhase, LLC

Discussant: Lawrence Yang, Columbia University Medical Center

10:45am – 10:55am **Introduction**

10:55am – 11:15am **Creating and Using “Fit for Purpose” Clinical Outcomes to Measure Clinically Relevant Benefits in Psychiatric Illnesses**
 George Garibaldi, F Hoffmann-La Roche

**10:45am – 12:15pm
(continued)** **New Frontiers in Measurement: The Revolution
will be Patient-centered**
Poinciana 3-4

11:15am – 11:35am **Advances in Negative Symptoms**
Brian Kirkpatrick, University of Nevada School of
Medicine

11:35am – 11:55am **Individualizing and Integrating Measurement Tools
for Social Cognition**
Anzalee Khan, ProPhase, LLC

11:55am – 12:15pm **Discussion**

10:45am – 12:15pm ***Defining Treatment Targets Across the
Depression Spectrum**
Salon 1 - Americana Ballroom

Chair: Philip Harvey, Miller School of Medicine, University of Miami

Discussant: Richard Keefe, Duke University Medical Center

10:45am – 10:55am **Introduction**

10:55am – 11:10am **Depression and Inflammation**
Charles Nemeroff, University of Miami, Leonard M.
Miller School of Medicine

11:10am – 11:25am **Mechanisms by which Depression Can Increase
Occurrence and Recurrence of Breast Cancer in
Women**
Marc Lippman, University of Miami Miller School of
Medicine

11:25am – 11:40am **Mifepristone Plasma Levels and Clinical Response
in Patients with Psychotic Depression**
Joseph Belanoff, Corcept Therapeutics

11:40am – 11:55am **Targeting Cognition for Treatment in Depression**
Philip Harvey, Miller School of Medicine, University of
Miami

11:55am – 12:15pm **Discussion**

**of special interest to clinicians*

10:45am – 12:15pm **The Challenges of Social Connectedness for Adolescents with Autism Spectrum Disorder: Implications for Research and Intervention**
Salon 2 - Americana Ballroom

Chair: Michael Murray, Penn State Milton S. Hershey Medical Center

Discussant: Alan Gelenberg, Journal of Clinical Psychiatry

10:45am – 10:55am **Introduction**

10:55am – 11:15am **Intranasal Oxytocin Enhances Social Brain Connectivity in ASD**
Allison Jack, Yale Child Study Center

11:15am – 11:35am **Effects of Beta-adrenergic Antagonism on Social Functioning in ASD**
David Beversdorf, Center for Translational Neuroscience University Hospital

11:35am – 11:55am **Efficacy of the Multi-media Social Skills Project for Adolescents with ASD**
Michael Murray, Penn State Milton S. Hershey Medical Center

11:55am – 12:15pm **Discussion**

12:15pm – 2:00pm **Lunch On Own**

2:00pm – 4:00pm ***Pharmaceutical Pipeline Presentations**
Salon 3 Americana Ballroom

Chair: Carlos Zarate, National Institute of Mental Health

2:00pm – 2:08pm **Metadoxine Extended Release (MDX): A Novel Drug Candidate for the Treatment of ADHD & Fragile X Syndrome**
Jonathan Rubin, Alcobra, Ltd.

2:08pm – 2:16pm **Dasotraline: A Novel Drug Candidate for the Treatment of ADHD**
Robert Goldman, Sunovion

**of special interest to clinicians*

2:00pm – 4:00pm (continued)	*Pharmaceutical Pipeline Presentations <i>Salon 3 Americana Ballroom</i>
2:16pm – 2:24pm	Discovery and Development of EMB-001 for the Treatment of Substance Use Disorders Michael Detke, Indiana University School of Medicine
2:24pm – 2:32pm	PH94B Nasal Spray as a PRN Treatment for Social Anxiety Disorder: A Phase 3 Pilot Trial Michael Liebowtiz, Columbia University
2:32pm – 2:40pm	The Antidepressant Activity of Basimglurant, a Novel mGlu5-NAM; a Randomized, Double-blind, Placebo-controlled Study in the Adjunctive Treatment of MDD Paul Tamburri, Roche
2:40pm – 2:48pm	Advancing Low Field Magnetic Stimulation (LFMS), A Potential Rapidly-acting Antidepressant Intervention Andrew Miller, Tal Medical
2:48pm – 2:56pm	A Single Intravenous Dose of the NMDA Receptor Glycine Site Modulator NRX-1074 Dose Dependently Reduced Depression Scores within 24 Hours in Subjects with Major Depressive Disorder (MDD) Ronald Burch, Naurex, Inc.
2:56pm – 3:04pm	A Randomized Placebo-controlled Adjunctive Trial of Riluzole in Treatment-resistant Major Depressive Disorder Sanjay Mathew, Baylor College of Medicine
3:04pm – 3:12pm	A Double-blind, Doubly-randomized, Placebo-controlled Study of Intranasal Esketamine in an Adaptive Treatment Protocol to Assess Safety and Efficacy in Treatment-resistant Depression Jaskaran Singh, Neuroscience TA, Janssen R & D, LLC, Janssen Pharmaceutical Companies of JNJ
3:12pm – 3:20pm	Non-invasive Neuromodulation with Trigeminal Nerve Stimulation in Major Depressive Disorder and Other CNS Disorders Ian Cook, UCLA Semel Institute for Neuroscience and Human Behavior

**2:00pm – 4:00pm
(continued)**

***Pharmaceutical Pipeline Presentations
*Salon 3 Americana Ballroom***

3:20pm – 3:28pm

A Double-blind, Placebo-controlled Study of the Antidepressant Effects of the mGlu2 Negative Allosteric Modulator RG1578 in Patients with Inadequate Response to Antidepressant Therapy
Daniel Umbricht, F. Hoffmann-La Roche, Ltd.,
Pharmaceutical Division

3:28pm – 3:36pm

ALKS 3831: A Novel Drug Candidate for the Treatment of Schizophrenia
Bernard Silverman, Alkermes, Inc.

3:36pm – 3:44pm

Bremelanotide for Hypoactive Sexual Desire Disorder: Analyses from a Phase 2B Dose-ranging Study
Anita Clayton, University of Virginia

4:00pm – 4:15pm

**Break
*Americana Foyer***

4:15pm – 5:30pm

**Special Session: Nomenclature Project
*Salon 3 – Americana Ballroom***

Chair: David Kupfer, University of Pittsburgh School of Medicine/Western Psychiatric Institute and Clinic

Discussant: William Potter, National Institute of Mental Health

Speakers:

Joseph Zohar, Chaim Sheba Medical Center

Pierre Blier, University of Ottawa Institute of Mental Health Research

David Kupfer, University of Pittsburgh School of Medicine/Western Psychiatric Institute and Clinic

6:15pm – 7:45pm

**New Investigators' Award Ceremony & Reception
(Invitation only)
*Cowrie 2***

AT-A-GLANCE

Tuesday, June 23, 2015

6:45am – 8:00am	15th Annual Fun Run/Walk – All Attendees Welcome! Meet on St. Moritz Lawn
6:45am – 8:15am	ASCP Board Meeting (Invitation only) Crown Conch
7:30am – 6:45pm	Registration Open Rotunda
7:30am – 8:30am	New Investigator Awardee Breakfast Roundtable (Invitation only) Neptune
7:30am – 9:00am	Morning Break Americana Foyer
8:30am – 10:00am	Regulatory Plenary: FDA and EMA Approaches to Innovation in Clinical Trials Salon 3 – Americana Ballroom
10:00am – 10:15am	Break Americana Foyer
10:15am – 11:15am	ASCP Lifetime Awardee Presentation - Nina Schooler: Perspectives on Schizophrenia and Psychosis: Pharmacologic Treatment and Course Salon 3 – Americana Ballroom
11:15am – 1:00pm	Poster Session I with Lunch Salon 4 – Americana Ballroom
1:00pm – 2:30pm	Panel Sessions

*Inflammation in Mood, Sleep & Obesity Location: Poinciana 1-2	*ADHD Across the Lifespan: Evidence-based Practices and Investigational Approaches Location: Poinciana 3-4	*Repurposing drugs: A New Look at the Pathophysiology and Therapeutic Management of Psychiatric Disorders Location: Salon 1 – Americana Ballroom	*Optimizing First Episode Schizophrenia Medication Treatment by Community Clinicians: The RAISE-ETP Model Location: Salon 2 – Americana Ballroom
---	---	---	---

**of special interest to clinicians*

2:30pm – 2:45pm

Break

Americana Foyer

2:45pm – 3:15pm

ASCP Business Meeting (ASCP Members Only)

Poinciana 1-2

3:15pm – 3:30pm

Break

Americana Foyer

3:30pm – 4:30pm

Individual Research Reports

Tools for Treating Depression during Pregnancy, New Treatments for Depression with Mixed Features and Schizophrenia, and Use of Technology to Assess Activities of Daily Living in Late-life	Advances in Clinical Trial Methodologies	Understanding Mechanisms of Maladaptive Behaviors and Diseases: Alcohol Consumption, Affective Processing, Alzheimer's Disease, and Early Onset Bipolar Disorder	Pharmacotherapy for Depression: Risks, Novel Compounds, and Prescribing Patterns	New Treatments for Schizophrenia
Location: Cowrie 1-2	Location: Poinciana 1-2	Location: Poinciana 3-4	Location: Salon 1 – Americana Ballroom	Location: Salon 2 – Americana Ballroom

4:30pm – 4:45pm

Break

Americana Foyer

4:45pm – 6:45pm

Special Session: How to Use the Model Psychopharmacology Curriculum in Various Teachings

Poinciana 1-2

4:45pm – 6:45pm

Workshops

NCCAM Workshop on Gut Microbes and the Brain: What We Know and Where We're Going	*The Perinatal Woman and Psychopharmacology: Optimizing Dosing and Infant Outcomes
Location: Salon 1 – Americana Ballroom	Location: Salon 2 – Americana Ballroom

6:45pm – 7:15pm

First Time Attendee Meet & Greet

Venus

7:15pm – 8:15pm

ASCP Reception

Americana Lawn

**of special interest to clinicians*

FULL SCHEDULE

Tuesday, June 23, 2015

6:45am – 8:00am	15th Annual Fun Run/Walk- All Attendees Welcome! Meet on St. Moritz Lawn
6:45am – 8:15am	ASCP Board Meeting (Invitation only) Crown Conch
7:30am – 6:45pm	Registration Open Rotunda
7:30am – 8:30am	New Investigator Awardee Breakfast Roundtable (Invitation only) Neptune
7:30am – 9:00am	Morning Break Americana Foyer
8:30am – 10:00am	Regulatory Plenary: FDA and EMA Approaches to Innovation in Clinical Trials Salon 3 – Americana Ballroom

Chair: Maurizio Fava, Massachusetts General Hospital

This session will provide perspectives on methodological and design innovations from US Food and Drug Administration (FDA) and European Medicines Agency (EMA). Dr. Tiffany Farchione, Deputy Director of the FDA's Division of Psychiatry Products (DPP) will discuss novel clinical endpoints. Specifically, she will discuss the review process for new clinical endpoints, both within and outside the qualification pathway. Dr. Luca Pani, Director General of the Italian Medicines Agency and member of the European Medicines Agency (EMA), will present an update on innovative conceptual approaches to clinical trial design and analysis both by the FDA and the EMA. New mechanisms of action and increasingly targeted therapies require innovation also in the design of clinical trials that should be reliable enough to support expedited development and authorization pathways for innovative drugs. New scientific and regulatory guidance is being drafted by FDA and EMA on aspects related to Adaptive Trial Design and study standardization, biomarkers in the early phase of development and surrogate outcome measures, clinical outcome assessments in the early phase of development, emerging technologies or new uses of existing technologies, innovative clinical trial design for pediatric therapeutics and risk-based monitoring of clinical trials. EMA is also working to be ready for the new scenario that will be introduced with the implementation of the new Clinical Trial Regulation that addresses the new scientific requirements, looking at the same time to create a favourable environment for innovative clinical trials in a global setting and to

8:30am – 10:00am (continued) **Regulatory Plenary: FDA and EMA Approaches to Innovation in Clinical Trials**
Salon 3 – Americana Ballroom

secure proper ethical considerations for all patient populations. Finally, Dr. Robert Temple, CDER's Deputy Center Director for Clinical Science and also Acting Deputy Director of the Office of Drug Evaluation I (ODE-I) at FDA, will review clinical trial design innovations and alternatives. There will be an informal discussion with the audience on these selected topics as well as other regulatory issues of common interest within this context.

8:30am – 8:45am Tiffany Farchione, US Food and Drug Administration
 8:45am – 9:00am Luca Pani, AIFA Italian Medicines Agency
 9:00am – 9:15am Robert Temple, US Food and Drug Administration
 9:15am – 10:00am Panel discussion and Q&A

10:00am – 10:15am **Break**
Americana Foyer

10:15am – 11:15am **ASCP Lifetime Awardee Presentation - Nina Schooler: Perspectives on Schizophrenia and Psychosis: Pharmacologic Treatment and Course**
Salon 3 – Americana Ballroom

Receipt of this honor provides the opportunity to review Dr. Schooler's personal understanding of schizophrenia and psychosis based on her research experiences and a personal reading of the literature. Dr. Schooler entered the field in 1963 during the initial burst of energy provided by the then new "neuroleptics" that offered prospect of treatment of psychosis.

In this talk she will review three broad areas of personal interest and activity:

- 1.) Long-term treatment with pharmacologic and psychosocial treatments: Evaluation of the effect of multimodal treatments has seen substantial transformation over time with the use of a range of research designs that provide different levels of information regarding efficacy and effectiveness.
- 2.) Treatment early in the course of illness: attention and interest in treatment early in the course of psychosis dates back to the early days of psychopharmacology, but studies of first episode psychosis have gained impetus in recent years and intersect with studies of multimodal treatment.
- 3.) Relations between researchers and the clinical populations that we serve and study: As the standards for gaining patient consent and collaboration have evolved, conducting research with patients in a range of settings has provided Dr. Schooler with the chance to learn from patients and their families.

11:15am – 1:00pm

Poster Session I with Lunch

Salon 4 – Americana Ballroom

****See Pages 73 through 86 for poster listing.***

Panel Sessions

1:00pm – 2:30pm

***Inflammation in Mood, Sleep & Obesity**

Poinciana 1-2

Chair: Erika Saunders, Penn State College of Medicine

Discussant: Marlene Freeman, Massachusetts General Hospital

1:00pm – 1:10pm

Introduction

1:10pm – 1:25pm

Inflammation in Bipolar Disorder: A Dietary Treatment Link

Erika Saunders, Penn State College of Medicine

1:25pm – 1:40pm

Influence of Depressive Symptomatology and TNFalpha on Weight Regain

Paul Burghardt, Wayne State University

1:40pm – 1:55pm

Phenotyping Insomnia: The Stress and Immune Interaction and its Clinical Implications

Julio Fernandez-Mendoza, Penn State Milton S. Hershey Medical Center

1:55pm – 2:10pm

Inflammation as a Predictive Biomarkers of Response to N-3 Fatty Acids in MDD: A Proof of Concept Study

Mark Rapaport, Emory University School of Medicine

2:10pm – 2:30pm

Discussion

1:00pm – 2:30pm

***ADHD Across the Lifespan: Evidence-based Practices and Investigational Approaches**

Poinciana 3-4

Chair: Jeffrey Newcorn, Icahn School of Medicine at Mount Sinai

Discussant: Mark Stein, University of Washington

1:00pm – 1:10pm

Introduction

1:10pm – 1:25pm

Stimulants: Current Best Practices and Drugs in Development

Ann Childress, Center for Psychiatry and Behavioral Medicine, Inc.

****of special interest to clinicians***

**1:00pm – 2:30pm
(continued)**

***ADHD Across the Lifespan: Evidence-based Practices and Investigational Approaches**
Poinciana 3-4

1:25pm – 1:40pm

Non-stimulant Medications: Current Best Practices and Investigational Drugs
Jeffrey Newcorn, Icahn School of Medicine at Mount Sinai

1:40pm – 1:55pm

Novel Interventions for ADHD: Can we Alter Trajectories to Improve Long-term Outcomes
Jeffrey Halperin, Queens College, City University of New York

1:55pm – 2:10pm

Non-pharmacological Approaches to Treating Core Symptoms and Related Impairments in Youth with ADHD
Anil Chacko, New York University

2:10pm – 2:30pm

Discussion

1:00pm – 2:30pm

***Repurposing Drugs: A New Look at the Pathophysiology and Therapeutic Management of Psychiatric Disorders**
Salon 1 – Americana Ballroom

Chair: Danielle Macedo, Neuropharmacology Laboratory, Universidade Federal do Ceará

Discussant: João de Quevedo, The University of Texas Health Science Center At Houston

1:00pm – 1:10pm

Introduction

1:10pm – 1:30pm

Carvedilol as Adjuvant Drug in Bipolar Disorder Treatment
David De Lucena, Federal University of Ceará

1:30pm – 1:50pm

Antipsychotic and Antidepressant Effects of Tetracyclines
Aline Monte, Federal University of Ceara

1:50pm – 2:10pm

Bipolar Depression and Negative Symptoms in Schizophrenia: Targeting Glutamate and its Role on Neuroinflammation
Clarissa Gama, UFRGS, HCPA, Porto Alegre, Brazil

2:10pm – 2:30pm

Discussion

**of special interest to clinicians*

1:00pm – 2:30pm

***Optimizing First Episode Schizophrenia
Medication Treatment by Community Clinicians:
The RAISE-ETP Model
*Salon 2 – Americana Ballroom***

Chair: Delbert Robinson, Hofstra NS-LIJ School of Medicine

Discussant: Joseph McEvoy, Medical College of Georgia

1:00pm – 1:10pm

Introduction

1:10pm – 1:30pm

Developing Medication Strategies for the RAISE-ETP Study

Delbert Robinson, Hofstra NS-LIJ School of Medicine

1:30pm – 1:50pm

**Use of a Patient-prescriber Computerized
Communication and Decision Support Tool in
RAISE-ETP: The Compass System**

Eric Achtyes, Michigan State University College of
Human Medicine

1:50pm – 2:10pm

**Medication Choices, Vital Signs and Self-reported
Side Effects in the RAISE-ETP RCT: Comparing
NAVIGATE, an Integrated Team Based Treatment
Program, to Community Care**

Nina Schooler, SUNY Downstate Medical Center

2:10pm – 2:30pm

Discussion

2:45pm – 3:15pm

**ASCP Business Meeting (ASCP Members Only)
*Poinciana 1-2***

3:15pm – 3:30pm

**Break
*Americana Foyer***

**of special interest to clinicians*

Individual Research Reports

3:30pm – 4:30pm **Tools for Treating Depression during Pregnancy, New Treatments for Depression with Mixed Features and Schizophrenia, and Use of Technology to Assess Activities of Daily Living in Late-Life**
Cowrie 1-2

Chair: Bradley Gaynes, University of North Carolina School of Medicine

3:30pm – 3:45pm **A New Tool to Aid Physicians and their Pregnant Patients – The Physician Reference Guide for the Treatment of Depression in Pregnancy with Antidepressant Medication**
Sophie Grigoriadis, Sunnybrook, University of Toronto

3:45pm – 4:00pm **Lurasidone for the Treatment of Major Depressive Disorder with Mixed Features: A Randomized, Double-blind, Placebo-controlled 6 Week Trial**
Josephine Cucchiaro, Sunovion Pharmaceuticals

4:00pm – 4:15pm **Physiologic and Clinical Effects of L-Methylfolate Supplementation in Schizophrenia: A Randomized Controlled Trial**
Joshua Roffman, Harvard Medical School/
Massachusetts General Hospital

4:15pm – 4:30pm **Age Differences in Instrumental Activities of Daily Living Assessed Using the Virtual Reality Functional Capacity Assessment Tool (VRFCAT)**
Alexandra Atkins, NeuroCog Trials




3:30pm – 4:30pm **Advances in Clinical Trial Methodologies**
Poinciana 1-2

Chair: Richard Keefe, Duke University Medical Center

3:30pm – 3:45pm **Exclusion Criteria in Placebo Controlled Antidepressant Efficacy Trials: A Review of the Past 20 Years of Published Research**
Mark Zimmerman, Brown University

3:30pm – 4:30pm (continued)	Advances in Clinical Trial Methodologies <i>Poinciana 1-2</i>
3:45pm – 4:00pm	Acetazolamide: A New Adherence Marker for Clinical Trials Aidan Hampson, National Institute of Health/NIDA
4:00pm – 4:15pm	Measuring Statistically and Clinically Meaningful Change in Clinical Trials: Moving away from Percent Change and Arbitrary Changes in Scores Anzalee Khan, ProPhase LLC
4:15pm – 4:30pm	Initial Severity not Related to Antidepressant Benefits or Placebo Response: A Patient Level Data Analysis from 34 Randomized Controlled Trials Jonathan Rabinowitz, Bar-Ilan University
3:30pm – 4:30pm	Understanding Mechanisms of Maladaptive Behaviors and Diseases: Alcohol Consumption, Affective Processing, Alzheimer's Disease, and Early Onset Bipolar Disorder <i>Poinciana 3-4</i>

Chair: Erika Saunders, Penn State College of Medicine

 3:30pm – 3:50pm	A Human Laboratory Study of Baclofen's Biobehavioral Mechanisms in Affecting Alcohol Consumption Mehdi Farokhnia, NIAAA, NIDA, NIH
 3:50pm – 4:10pm	Atrophy Patterns in Alzheimer's Disease Exhibit Network Properties Ram Bishnoi, UTHSCSA
 4:10pm – 4:30pm	Affective Processing in Pediatric Bipolar Disorder and Offspring of Bipolar Parents Isabelle Bauer, University of Texas at Houston



= New Investigator

3:30pm – 4:30pm

Pharmacotherapy for Depression: Risks, Novel Compounds, and Prescribing Patterns
Salon 1 – Americana Ballroom

Chair: Carlos Zarate, National Institute of Mental Health

3:30pm – 3:45pm

Lethality of Medications Used to Treat Depression in Overdose

J. Craig Nelson, University of California San Francisco

3:45pm – 4:00pm

Randomized, Proof-of-Concept Trial of Low Dose Naltrexone for Patients with Breakthrough Symptoms of Major Depressive Disorder on Antidepressants

David Mischoulon, Depression Clinical and Research Program

4:00pm – 4:15pm

ALKS 5461 as Adjunctive Treatment of Major Depressive Disorder: Phase 3, Randomized, Double-blind Study (FORWARD-1) Evaluating Two Titration Schedules

Lauren DiPetrillo, Alkermes

4:15pm – 4:30pm

The ASCP Survey of Psychopharmacologists' Prescribing Patterns for Mood Disorders

Joseph Goldberg, Icahn School of Medicine at Mount Sinai

3:30pm – 4:30pm

New Treatments for Schizophrenia
Salon 2 – Americana Ballroom

Chair: Nina Schooler, SUNY Downstate Medical Center

3:30pm – 3:45pm

A Phase 2, Randomized, Olanzapine-controlled Study of the Safety, Tolerability, and Efficacy of ALKS 3831 in Adults with Schizophrenia

Bernard Silverman, Alkermes, Inc.

3:45pm – 4:00pm

Efficacy and Safety of Brexpiprazole, a New Investigational Serotonin-dopamine Activity Modulator, for Treatment of Schizophrenia

Ross Baker, Otsuka

3:30pm – 4:30pm (continued)	New Treatments for Schizophrenia <i>Salon 2 – Americana Ballroom</i>
4:00pm – 4:15pm	Efficacy and Safety of Aripiprazole Lauroxil in Acute Exacerbation of Schizophrenia: Results from a Double-blind, Placebo-controlled Study Leslie Citrome, New York Medical College
4:15pm – 4:30pm	Results from QUALIFY, a Head-to-head Clinical Study of Aripiprazole Once-monthly and Paliperidone Palmitate in Schizophrenia Steven Potkin, University of California, Irvine
4:30pm – 4:45pm	Break

Special Session

4:45pm – 6:45pm	How to Use the Model Psychopharmacology Curriculum in Various Teachings <i>Poinciana 1-2</i>
------------------------	---

Chair: Ira Glick, Stanford University School of Medicine

Workshops

4:45pm – 6:45pm	NCCAM Workshop on Gut Microbes and the Brain: What We Know and Where We're Going <i>Salon 1 – Americana Ballroom</i>
------------------------	---

Chair: Emmeline Edwards, National Institutes of Health/NCCAM

Co-Chair: David Shurtleff, National Center for Complementary & Alternative Medicine

4:45pm – 4:50pm	Introduction
4:50pm – 5:10pm	The American Gut Project Daniel McDonald, National Institutes of Health
5:10pm – 5:35pm	The Microbiota-Gut-Brain Axis: Intestinal Dysbiosis and the Regulation of Behavior Melanie Gareau, University of California, Davis
5:35pm – 5:50pm	The Microbiome-Gut-Brain Axis in Pain and Anxiety: Top Down or Bottom Up? Kirsten Tillisch, David Geffen School of Medicine at UCLA
5:50pm – 6:45pm	Discussion

4:45pm – 6:45pm

***The Perinatal Woman and Psychopharmacology:
Optimizing Dosing and Infant Outcomes**
Salon 2 - Americana Ballroom

Chair: Crystal Clark, Northwestern University

4:45pm – 4:50pm

Introduction

4:50pm – 5:10pm

**Pregnancy and Anti-epileptic Drugs in Women with
Epilepsy: A Neurologist's Approach**

Elizabeth Gerard

Feinberg School of Medicine, Northwestern University

5:10pm – 5:35pm

**Optimal Use of SSRI Antidepressants during
Pregnancy and Postpartum**

Katherine Wisner, Northwestern University Feinberg
School of Medicine

5:35pm – 5:50pm

**Gestational Diabetes and Weight-gain Inducing
Drugs: Implications for Treatment Planning and
Management of Metabolic Risks in Women with
Mood Disorders during Pregnancy**

Dorothy Sit, Western Psychiatric Institute and Clinic

5:50pm – 6:10pm

**Lamotrigine, Dosing, and the Bipolar Woman:
Pharmacokinetics for Therapeutic Drug Monitoring
and Dosing**

Crystal Clark, Northwestern University

6:10pm – 6:45pm

Discussion

6:45pm – 7:15pm

First Time Attendee Meet & Greet
Venus

7:15pm – 8:15pm

ASCP Reception
Americana Lawn

AT-A-GLANCE

Wednesday, June 24, 2015

7:00am – 8:30am	ASCP Steering Committee Meeting (Invitation only) Triton
7:30am – 6:00pm	Registration Open Rotunda
7:30am – 8:30am	New Investigator Awardee Breakfast Roundtable (Invitation only) Neptune
7:30am – 9:00am	Morning Break Americana Foyer
8:15am – 9:45am	*Keynote Session: Changing the Paradigm from Diagnose and Treat to Predict and Preempt Salon 3 – Americana Ballroom
9:45am – 10:00am	Break Americana Foyer
10:00am – 12:00pm	Plenary Session – NIH Institute Directors Salon 3 – Americana Ballroom
12:00pm – 2:00pm	Poster Session II with Lunch Salon 4 – Americana Ballroom
2:00pm – 3:30pm	*Updates Session – Clinical Updates in Pharmacology Salon 3 – Americana Ballroom
3:30pm – 3:45pm	Break Americana Foyer
3:45pm – 5:45pm	Workshops

How should We Define Resistance in Depression?	*Long Acting Injectables in the Treatment of Schizophrenia: Missed Opportunities and Challenges
Location: Salon 1 – Americana Ballroom	Location: Salon 2 – Americana Ballroom

**of special interest to clinicians*

[illegible]

FULL SCHEDULE

Wednesday, June 24, 2015

7:00am – 8:30am	ASCP Steering Committee Meeting (Invitation only) <i>Triton</i>
7:30am – 6:00pm	Registration Open <i>Rotunda</i>
7:30am – 8:30am	New Investigator Awardee Breakfast Roundtable (Invitation only) <i>Neptune</i>
7:30am – 9:00am	Morning Break <i>Americana Foyer</i>

8:15am – 9:45am	*Keynote Session: Changing the Paradigm from Diagnose and Treat to Predict and Preempt <i>Salon 3 – Americana Ballroom</i>
-----------------	--

Chair: Hussein K. Manji, Johnson & Johnson

Traditionally therapies have been developed for intervention in clinically diagnosed patients with established pathologies and overt symptoms. There are many drivers for this paradigm, including the facility of performing clinical trials in easy to identify populations with room to show clinical improvement, and patients to adhere to therapies that address clear and present deficits. However, it is clear that to have markedly improved outcomes for individuals suffering from serious neuropsychiatric illnesses, we believe that interventions will need to move earlier in the disease continuum, with the ultimate goal of shifting from the current 'diagnose and treat' to a 'predict and preempt' paradigm. In most neurodegenerative diseases, due to the existence of 'cognitive reserve' and plasticity of synapses and circuits, clinically discernable symptoms appear much after considerable progression of underlying pathology, by which time irreversible cellular and physiological damage has already occurred. Likewise, other neuropsychiatric disorders are characterized by recurrences and relapses, each of which causes a precipitous, irreversible progression of pathophysiology. As a result, CNS diseases are particularly suitable for this shift towards 'disease interception' via earlier detection and treatment in prodromal stages or prediction and prevention of relapses and reoccurrences. While earlier disease interception

**of special interest to clinicians*

**8:15am – 9:45am
(continued)**

***Keynote Session: Changing the Paradigm from
Diagnose and Treat to Predict and Preempt
Salon 3 – Americana Ballroom**

can bring considerable value to individual patients, health-care systems and society at large, many challenges abound in the successful discovery, development and adoption of therapies that target earlier stages of disease. These challenges range from scientific – improved understanding of causative biological processes and means to diagnose them early, to regulatory – e.g. development of pathways that allow for approval of interventions which may show meaningful bending of the disease and ‘cost of care’ curve only years down the road. In this session we will explore these challenges and novel solutions that will allow us to intervene early and halt these diseases before they cause irreparable damage and devastation. The outstanding group of panelists will discuss novel technological approaches to facilitating disease interception, and early intervention approaches in a variety of neuropsychiatric conditions including autism, schizophrenia and recurrent mood disorders.

8:15am – 8:20am

Introduction

Husseini K. Manji, Johnson & Johnson

8:20am – 8:35am

**Data and Informatics Challenges in Moving from
a ‘Diagnose and Treat’ to a ‘Predict and Preempt’
Paradigm**

Vaibhav Narayan, Johnson & Johnson

8:35am – 8:50am

**Early Risk Detection Offers Promise for Altering
the Course of Brain and Behavioral Development
in Autism**

Geraldine Dawson, Duke University

8:50am - 9:05am

The RAISE Study: What have we Learned?

John Kane, The Zucker Hillside Hospital

9:05am – 9:20am

**First Steps: Initial Efforts to Develop Preventative
Interventions for Youth at Risk for Bipolar Disorder**

Ellen Frank, University of Pittsburgh School of
Medicine

9:20am – 9:45am

Discussion

9:45am – 10:00am

Break

Americana Foyer

**of special interest to clinicians*

**10:00am – 12:00pm Plenary Session – NIH Institute Directors
Salon 3 Americana Ballroom**

Chair: Michael Thase, Perelman School of Medicine at the University of Pennsylvania

This year's Institute Director's Plenary session will bring together directors from various NIH institutes who all have a similar goal of searching for new approaches in the research of mental disorders. Each director will have ten minutes to discuss what activities are going on within their institute regarding this goal.

Steven Zalcman, representing NIMH, will begin the session discussing how to bend the curve in psychiatric therapeutics by leveraging advances in clinical neuroscience. Three major concepts will be highlighted: (1) Transforming diagnostics: as mental disorders are brain disorders, 21st century psychiatric diagnosis should be rooted in biology and behavior; (2) Transforming therapeutics: emphasizing an experimental medicine paradigm focused on target identification and validation, trials must be designed to be equally informative with positive or negative data; and (3) Transforming culture: shifting the culture from "my data" to data mining, the bywords being standardization, integration, and sharing.

Phil Skolnick, representing NIDA, will discuss the challenges of developing "other than abstinence" outcome measures in medication trials for substance use disorders (SUDs). At present, a period of sustained abstinence appears required for regulatory approval of a medication to treat stimulant (cocaine, methamphetamine), cannabis and nicotine use disorders. For alcohol use disorders, the FDA has adopted the "percentage of subjects with no heavy drinking days" as an endpoint for pharmacotherapy trials, indicating a potential path forward for developing analogous, non-abstinence endpoints for SUD trials. However, reductions in drug use per se (short of abstinence) must have prognostic value in order for the FDA to consider it as an acceptable basis for approval. Thus, even if a medication can sustain reductions in drug use, the challenge is to demonstrate that this "success" is accompanied by benefits that accrue in dimensions which will be readily understood by physicians, patients, their families and of sufficient value to be reimbursed by third party payers.

Rajesh Raganathan from the National Institute of Neurological Disorders and Stroke, will describe the Office of Translational Research's role in facilitating the preclinical discovery and development of new therapeutic interventions for neurological disorders. The OTR provides funding (approximately \$100 million annually) in grants and resources to industry and university researchers to advance early-stage neurological technologies, devices, and therapeutic programs to industry adoption (i.e., investor funding and corporate partnerships). Significant emphasis is placed on engaging other

**10:00am – 12:00pm
(continued)**

**Plenary Session – NIH Institute Directors
*Salon 3 Americana Ballroom***

stakeholders, such as pharmaceutical, biotechnology, venture capital, and patient advocacy organizations to ensure that projects are adequately de-risked to accelerate downstream investments and to develop much-needed therapies for people suffering from neurological disorders.

David Shurtleff will present the NCCIH research priorities and funding opportunities such as Multi-IC program announcement on Advancing Translational and Clinical Probiotic/Prebiotic and Human Microbiome Research and NICCH's Exploratory Clinical Trials of Mind and Body Interventions program announcements among other priorities and highlights.

Lastly, Richard Nakamura will discuss the Center for Scientific Review's steps to measure and improve the performance of peer review. The session will continue with an open dialogue Q&A session with audience interaction.

Speakers:

Steven Zalcman, NIMH

Phil Skolnick, NIDA

Rajesh Ranganathan, NINDS

David Shurtleff, NCCIH

Richard Nakamura, CSR

12:00pm – 2:00pm

**Poster Session II with Lunch
*Salon 4 - Americana Ballroom***

****See Pages 87 through 100 for poster listing.***

2:00pm – 3:30pm

***Clinical Updates in Pharmacology
*Salon 3 – Americana Ballroom***

Chair: Holly Swartz, University of Pittsburgh School of Medicine

Recent advances in clinical neuroscience have led to the development of novel treatments for mood, disorders. The purpose of this symposium is to provide an overview of the latest developments in the pharmacological treatments for pregnant patients and depressed youth and to provide an overview of NMDA antagonists.

Dr. Freeman will discuss psychopharmacology and the pregnant patient with a focus on developing an accurate risk/benefit analysis of in utero psychotropic exposure. Dr. Freeman will also discuss the FDA's 2014 draft recommendation guide for new labeling content and formatting to replace its long-held convention of letter category assignment for pregnancy risk.

****of special interest to clinicians***

**2:00pm – 3:30pm
(continued)**

***Clinical Updates in Pharmacology
Salon 3 – Americana Ballroom**

The challenges and implications of a refined risk/benefit approach to the treatment of psychiatric disorders during pregnancy will be discussed.

Dr. Wagner will review the current evidence base for the treatment of major depressive disorder in children and adolescents and will discuss pharmacologic strategies for treatment resistant depression in youth.

Finally, Dr. Zarate will discuss the glutamate neurotransmitter system and the attention this system has received in recent years as a path for developing next generation therapeutics for mood disorders. He will discuss studies showing that a single subanesthetic dose infusion of the non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist ketamine has been shown to have rapid and potent antidepressant effects in treatment-resistant major depressive disorder and bipolar disorder. Dr. Zarate will review subsequent preclinical and clinical studies exploring glutamatergic mechanisms of antidepressant action including current efforts to understand the neurobiological mechanisms responsible for ketamine's antidepressant activity in biologically enriched subgroups and to identify treatment response biomarkers to personalize antidepressant selection. Other NMDA receptor antagonists (MK-0657 [CERC-301], AZD6765) which have been studied both preclinically and clinically will also be discussed.

2:00pm – 2:20pm

Psychopharmacology and the Pregnant Patient
Marlene Freeman, Massachusetts General Hospital

2:20pm – 2:40pm

Depression in Youth
Karen Wagner, University of Texas Medical Branch

2:40pm – 3:00pm

NMDA Antagonists
Carlos Zarate, National Institute of Mental Health

3:00pm – 3:30pm

Discussion

3:30pm – 3:45pm

Break
Americana Foyer

**of special interest to clinicians*

Workshops

3:45pm – 5:45pm **How should we Define Resistance in Depression?**
Salon 1 - Americana Ballroom

Chair: Maurizio Fava, Massachusetts General Hospital

Discussant: Tiffany Farchione, US Food and Drug Administration

3:45pm – 3:55pm **Introduction**

3:55pm – 4:15pm **Definition and Prevalence of Drug Resistant Depression**

Madhukar Trivedi, UT Southwestern Medical Center

4:15pm – 4:35pm **Prospective versus Retrospective Assessment of Resistance in Depression**

George Papakostas, Massachusetts General Hospital

4:35pm – 4:55pm **Critical Methodological Decisions in the Design and Implementation of Trials in Resistant Depression**

Maurizio Fava, Massachusetts General Hospital

4:55pm – 5:15pm **Biomarkers to Identify Populations at Risk for Resistance to Antidepressant Therapy**

Gerard Sanacora, Yale University Medical School

5:15pm – 5:45pm **Discussion**

3:45pm – 5:45pm

***Long Acting Injectables in the Treatment of Schizophrenia: Missed Opportunities and Challenges**
Salon 2 – Americana Ballroom

Chair: Jean-Pierre Lindenmayer, New York University

Discussant: Stephen Marder, Semel Institute at UCLA

3:45pm – 3:55pm

Introduction

3:55pm – 4:15pm

Long Acting Injectables in the Treatment of Schizophrenia: Missed Opportunities and Challenges

Steven Potkin, University of California - Irvine, School of Medicine

4:15pm – 4:35pm

The Role of LAIs in the Treatment of Schizophrenia: A Meta-analysis of Controlled Outcome Data

Ira Glick, Stanford University School of Medicine

4:35pm – 4:55pm

Use of Long Acting Paliperidone Palmitate in a Comparative Effectiveness Study of Persons with Schizophrenia and a History of Contact with the Criminal Justice System

Larry Alphs, Janssen

4:55pm – 5:15pm

Patient Outcomes within Schizophrenia Treatment: A Look at the Role of Long-acting Injectable Antipsychotics

Rimal Bera, University of California, Irvine School of Medicine

5:15pm – 5:45pm

Discussion

**of special interest to clinicians*

[illegible]

AT-A-GLANCE

Thursday, June 25, 2015

7:30am – 12:00pm **Registration Open**
Rotunda

7:30am – 9:00am **Morning Break**
Americana Foyer

8:30am – 10:00am **Panel Sessions**

*Clinical Staging: A New Approach to Bipolar Disorder Location: Poinciana 1-2	Mind the Gap: Searching for Measurements to More Accurately Measure Symptoms in CNS Trials Location: Poinciana 3-4	New NIMH Initiatives Aimed at Developing New Treatments and/or Treatment Approaches Location: Salon 2 – Americana Ballroom	Diagnosis and Treatment for Low Sexual Desire/Arousal in Women Location: Salon 1 – Americana Ballroom
--	--	---	---

10:00am – 10:15am **Break**
Americana Foyer

10:15am – 11:45am **Plenary: Regulatory Wrap-up Session**
Salon 3 – Americana Ballroom

12:00pm **Meeting Adjourns**

Thursday

**of special interest to clinicians*

[illegible]

FULL SCHEDULE

Thursday, June 25, 2015

7:30am – 12:00pm **Registration Open**
Rotunda

7:30am – 9:00am **Morning Break**
Americana Foyer

Panel Sessions

8:30am – 10:00am **Mind the Gap: Searching for Measurements to
More Accurately Measure Symptoms in CNS Trials**
Poinciana 3-4

Chair: Jan Sedway, inVentiv Health Clinical

Discussant: Christine Moore, inVentiv Health Clinical

8:30am – 8:40am **Introduction**

8:40am – 9:00am **The Patient-centered Outcome Gap in CNS
Clinical Trials: Perspectives from a Card-carrying
Psychiatric Health Services Researcher**
Bradley Gaynes, University of North Carolina

9:00am – 9:20am **Sins of the Father: The PANSS for the Next
30 Years**
Mark Opler, ProPhase, LLC

9:20am – 9:40am **Measures of Cognition in Clinical Trials:
Are we being Sensitive Enough?**
Chris Brady, inVentiv Health Clinical

9:40am – 10:00am **Discussion**

8:30am – 10:00am **Diagnosis of and Treatment for Low Sexual Desire/Arousal in Women**
Salon 1 – Americana Ballroom

Chair: Christina Chang, US Food and Drug Administration

Discussant: Alan Gelenberg, Journal of Clinical Psychiatry

8:30am – 8:40am **Introduction**

8:40am – 9:00am **Current FDA Regulatory Framework for Products Intended to Treat Low Sexual Desire/Interest and Low Sexual Arousal in Women**
Christina Chang, US Food and Drug Administration

9:00am – 9:20am **Treatments for Reduced Sexual Desire/Arousal in Women – Gynecological Perspective**
Margery Gass, The North American Menopause Society

9:20am – 9:40am **Diagnosis/Management of Patients who have Antidepressant-induced Sexual Dysfunction**
Paula Hensley, University of New Mexico Health Science Center

9:40am – 10:00am **Discussion**

8:30am – 10:00am ***Clinical Staging: A New Approach to Bipolar Disorder**
Poinciana 1-2

Chair: Flavio Kapczinski, The University of Texas Health Science Center at Houston

Discussant: João de Quevedo, The University of Texas Health Science Center at Houston

8:30am – 8:40am **Introduction**

8:40am – 9:00am **Cognitive Impairment as a Marker of Late-stage Late-life Depression**
Breno Satler Diniz, Federal University of Minas Gerais

**of special interest to clinicians*

8:30am – 10:00am (continued)	*Clinical Staging: A New Approach to Bipolar Disorder <i>Poinciana 1-2</i>
9:00am – 9:20am	Neuroimaging Evidence of Progression of Bipolar Disorder Sudhakar Selvaraj, The University of Texas Health Science Center at Houston
9:20am – 9:40am	Neuroprogression and Bipolar Disorders: Brain Imaging and Neurocognitive Studies Jair Soares, University of Texas School of Medicine at Houston
9:40am – 10:00am	Discussion
8:30am – 10:00am	New NIMH Initiatives Aimed at Developing New Treatments and/or Treatment Approaches <i>Salon 2 – Americana Ballroom</i>

Chair and Discussant: William Potter, National Institutes of Mental Health

8:30am – 8:40am	Introduction
8:40am – 9:00am	The NIMH Research Domain Criteria (RDoC) Project and its Relevance to the Experimental Medicine Paradigm Steven Zalcman, National Institute of Mental Health/NIH
9:00am – 9:20am	The Fast-fail Trials (FAST) Initiative: Goals and Specific Projects Andrew Krystal, Duke Clinical Research Institute/Duke University School of Medicine
9:20am – 9:40am	The NIMH-funded Rapidly-acting Treatments for Treatment-resistant Depression (RAPID) Project Maurizio Fava, Massachusetts General Hospital
9:40am – 10:00am	Discussion

10:00am – 10:15am **Break**
Americana Foyer

10:15am – 11:45am **Plenary: Regulatory Wrap-up Session**
Salon 3 – Americana Ballroom

Chair: Maurizio Fava, Massachusetts General Hospital

Speakers: Tiffany Farchione, US Food and Drug Administration
Luca Pani, AIFA Italian Medicines Agency

12:00pm **Meeting Adjourns**

Tuesday, June 23, 2015

Poster Session I

1. * **The Antidepressant Activity of Basimglurant, a Novel mGlu5-NAM; a Randomized, Double-blind, Placebo-controlled Study in the Adjunctive Treatment of MDD**
Paul Tamburri, Roche
Jorge Quiroz, Dennis Deptula, Ludger Banken, Ulrich Beyer, Paulo Fontoura, Luca Santarelli
2. * **Dasotraline: A Novel Drug Candidate for the Treatment of ADHD**
Robert Goldman, Sunovion
Kenneth S. Koblan, Seth C. Hopkins, Antony Loebel
3. **OPEN BOARD**
4. * **Non-invasive Neuromodulation with Trigeminal Nerve Stimulation in Major Depressive Disorder and Other CNS Disorders**
Ian Cook, UCLA Semel Institute for Neuroscience and Human Behavior
Andrew Leuchter, Christopher DeGiorgio
5. * **Bremelanotide for Hypoactive Sexual Desire Disorder: Analyses from a Phase 2B Dose-ranging Study**
Anita Clayton, University of Virginia
Carl Spana, Robert Jordan
6. * **ALKS 3831: A Novel Drug Candidate for the Treatment of Schizophrenia**
Bernard Silverman, Alkermes, Inc.
Mark Todtenkopf, Ying Jiang, Sanjeev Pathak, Anjana Bose, Daniel Deaver, Srdjan Stankovic, Elliot Ehrich
7. * **A Double-blind, Placebo-controlled Study of the Antidepressant Effects of the mGlu2 Negative Allosteric Modulator RG1578 in Patients with Inadequate Response to Antidepressant Therapy**
Daniel Umbricht, F. Hoffmann-La Roche, Ltd., Pharmaceutical Division
Markus Niggli, Patricia Sanwald-Ducray, Dennis Deptula, Rema Moore, Waltraud Grünbauer, Lauren Boak, Silvia Gatti, Paulo Fontoura
8. * **Metadoxine Extended Release (MDX): A Novel Drug Candidate for the Treatment of ADHD & Fragile X Syndrome**
Jonathan Rubin, Alcobra, Ltd.
Yaron Daniely

* = Pharma Pipeline

9. * **A Single Intravenous Dose of the NMDA Receptor Glycine Site Modulator NRX-1074 Dose Dependently Reduced Depression Scores within 24 Hours in Subjects with Major Depressive Disorder (MDD)**
 Ronald Burch, Naurex, Inc.
 Wen Yu, M. Amin Khan, Lee Bastin, Jeffrey Burgdorf, Joseph R. Moskal

10. * **A Randomized Placebo-controlled Adjunctive Trial of Riluzole in Treatment-resistant Major Depressive Disorder**
 Sanjay Mathew, Baylor College of Medicine
 Maurizio Fava, Ralitza Guerguieva, Gerard Sanacora

11. * **A Double-blind, Doubly-randomized, Placebo-controlled Study of Intranasal Esketamine in an Adaptive Treatment Protocol to Assess Safety and Efficacy in Treatment-resistant Depression**
 Jaskaran Singh, Neuroscience TA, Janssen R&D, LLC, Janssen Pharmaceutical Companies of JNJ

12. * **Discovery and Development of EMB-001 for the Treatment of Substance Use Disorders**
 Michael Detke, Indiana University School of Medicine
 Nicholas Goeders, Glenn Guerin, Carol Gloff, Gary Connor, Doug Feltner


13. * **PH94B Nasal Spray as a PRN Treatment for Social Anxiety Disorder: A Phase 3 Pilot Trial**
 Michael Liebowtiz, Columbia University
 Louis Monti, Rita Hanover, Ann Draine

14. **Skeletal Effects of Psychostimulants in Youth**
 Chadi Calarge, Baylor College of Medicine
 Janet Schlechte, Trudy Burns, Babette Zemel

15. **A Comparison of Parent and Teacher Sensitivity to Side Effects of Medications for ADHD**
 Molly Leavitt, University of Cincinnati
 Leanne Tamm, Tanya Froehlich, Jeffery Epstein

16. **The Management of Attention Deficit Hyperactivity Disorder and Concurrent Substance Use**
 Roxanne Lewin, NYU School of Medicine
 Julia Holtmann, Julia Arnsten, Merrill Herman

* = Pharma Pipeline

17. **OPEN BOARD**
18. **Pharmacokinetics of Novel Methylphenidate Extended-release Oral Disintegrating Tablets for ADHD**
Mark Tengler, Neos Therapeutics
Russ McMahan, Jeffrey Stark, Carolyn Sikes
19. **Brain Surgery in Smoke (Coca Paste) Cocaine-addicted Patients: Review of Long Term Results**
Teobaldo Llosa, Cocamedica Research Institute
20. **Opioid Receptor Antagonist Odelepran does not Cause Addiction in Wistar Rats**
Elvira Mukhametshina, R-Pharm
Michael Samsonov, Maxim Lovat, Olga Averina, Marina Belopolskay, Vladimir Pavshincev, Michael Egorov
21. **Exploring Relationships between Medical Marijuana Laws and Cannabinoid Related Treatment Admissions Using the Treatment Episode Data Set for Admissions (TEDS-A)**
Christian Teter, University of New England
Jorge Bolinaga, Ryan Warren, Lindsey McIver
22. **A Double-blind, Randomized, Placebo-controlled, Flexible-dose Study of Vilazodone in Patients with Generalized Anxiety Disorder**
David Sheehan, University of South Florida College of Medicine
Suresh Durgam, Carl Gommoll, Giovanna Forero, Rene Nunez, Xiongwen Tang, Maju Mathews
-  23. **Evaluation of Tryptophan, Kynurenine and Serotonin Plasmatic Levels in a Large Population of Aggressive Prisoners**
Stefano Comai, McGill University, Department of Psychiatry
Antonella Bertazzo, Jeanne Vachon, Marc Daigle, Jean Toupin, Gustavo Turecki, Gilles Côté, Gabriella Gobbi




= New Investigator

24. **Healthy Brain Activation to Attentional and Emotional Stimuli over Eight Weeks: Preliminary Data for Staging Mood Disorders Treatment using fMRI**
David Fleck, University of Cincinnati College of Medicine
James Eliassen, Matthew Norris, Caleb Adler, Melissa DelBello, Jeffrey Welge, Thomas Blom, Amanda Stover, Jing-Huei Lee, Stephen Strakowski
-  25. **Meta-analysis of Cytokine Alterations in Chronically Ill Psychiatric Patients: Comparisons between Schizophrenia, Bipolar Disorder, and Depression**
David Goldsmith, Emory University School of Medicine, Department of Psychiatry
Brian Miller, Mark Rapaport
26. **An 8-Week, Double-blind, Placebo-controlled Study of Cariprazine Monotherapy for the Treatment of Bipolar I Depression**
Suresh Durgam, Forest Research Institute, A Subsidiary of Actavis PLC
Alan Lipschitz, Hua Guo, Willie Earley, István Laszlovszky, György Németh, Lakshmi N. Yatham
27. **The Preventive Effect of Minocycline in GBR 12909-Induced Manic-Like Behavior**
Aline Monte, Federal University of Ceara
Ana Isabelle de Góis Queiroz, Adriano José Maia Chaves Filho, Tatiane da Silva Araujo, Michel de Jesus Souza Machado, Camila Nayane Carvalho Lima, Francisca Taciana Sousa Rodrigues, David Freitas de Lucena, João Quevedo, Danielle Macêdo
28. **Subjective and Objective Sleep in Symptomatic Bipolar Disorder Subjects**
Venkatesh Krishnamurthy, Penn State Milton S. Hershey Medical Center, Department of Psychiatry
Aubrey Reider, Erika Saunders
29. **Symptomatic and Functional Recovery in Lurasidone-treated Patients with Bipolar Depression**
Antony Loebel, Sunovion Pharmaceuticals, Inc.
Cynthia Siu, Krithika Rajagopalan, Andrei Pikalov, Josephine Cucchiario, Terence Ketter



= New Investigator

30. **Efficacy and Safety of Asenapine 5 mg BID and 10 mg BID in Adults with a Manic or Mixed Episode Associated with Bipolar I Disorder**
 Pauline Patrick, Actavis
 Roger S. McIntyre, Ronald Landbloom, Mary Mackle, Xiao Wu, Linda Kelly, Linda Snow-Adami, Maju Mathews, Carla Hundt

-  31. **Resilience in High-risk Offspring of Mothers with Bipolar Disorder: A Longitudinal Investigation**
 Diana Simeonova, Emory University School of Medicine Department of Psychiatry
 Frances Lee, Hsu Hui-Chin, Juul Sarah, Mast Jill, Goldsmith Toby, Nguyen Theresa, Stagnaro Emily, Craighead Edward, Ressler Kerry

32. **Long-term Use of Lurasidone in Patients with Bipolar Disorder: Safety and Effectiveness Over 2 Years of Treatment**
 Andrei Pikalov, Sunovion Pharmaceuticals, Inc.
 Joyce Tsai, Yongcai Mao, Josephine Cucchiaro, Antony Loebel

33. **Lurasidone Pharmacokinetics and Safety Profile in Pediatric Patients with Psychiatric Disorders**
 Andrei Pikalov, Sunovion Pharmaceuticals, Inc.
 Robert Findling, Yu-Yuan Chiu, Robert Silva, Robert Goldman, Fengbin Jin, Antony Loebel

34. **Impediments to Clinical Trial Eligibility for Pharmacologic Interventions in Autism**
 Lindsay DeVane, Medical University of South Carolina, Department of Psychiatry & Behavioral Sciences
 Charles Jane, Ruth K. Abramson, John Williams, Laura A Carpenter, Mark E. Geesey, Catharine Bradley, Sarah Ravan, M. Frampton Gwynette, Marcus Kruesi, Eve Spratt, H.H. Wright

35. **Low Vitamin D Level Interacts with Peripheral Body Fat to Predict Hepatic Fat Content in Antipsychotic Treated and Non-treated Youth**
 Ginger Nicol, Washington University School of Medicine
 Michael Yingling, Eric Lenze, John Newcomer

36. **The Suicide Ideation and Behavior Assessment Tool (SIBAT): Development of a Novel Measure of Suicidal Ideation/Behavior and Perceived Risk of Suicide**
 Carla Canuso, Janssen Research & Development
 Larry Alphs, David Williamson



= New Investigator

37. **US and Eastern and Central European Rater Performance Administering the Mini International Neuropsychiatric Interview (MINI): Are there Implications for Training and Sponsor Global Site Selection?**
 Elan Cohen, Worldwide Clinical Trials
 Rolana Avrumson, Bethanne Friedmann, Kim Baldwin, Melissa Carbo, Natalie Glaug, Andrew Komorowsky, Sean Meighan, John Perrett, Colleen Rock, Michael Murphy
38. **Drug-induced Neurocognitive Changes on Choice Reaction Time in CNS Polydrug Recreational Users**
 Talar Hopyan, INC Research
 Beatrice Setnik
39. **Determining and Addressing Recruitment Challenges in an Efficacy Trial in Bipolar Disorder, Depressed Phase**
 Alisha Coulson, University of Kansas School of Medicine
 Alisha Oelke, Matthew Macaluso, Brent Wurfel, Jonathan Savitz, Matt Meyer, Wayne C. Drevets, Sheldon Preskorn
40. **Development and Application of an Adherence Metric Derived from Population Pharmacokinetics to Inform Clinical Trial Enrichment**
 Jonathan Knights, Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)
 Shashank Rohatagi
41. **Going Digital in Clinical Development**
 Deborah Profit, Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)
 Jonathan Knights, Erica Lawson, Shashank Rohatagi, Timothy Peters-Strickland, Margaretta Nyilas
42. **Optimization of a Digital Health Feedback System in Psychiatry**
 Shashank Rohatagi, Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)
 Deborah Profit, Jonathan Knights, Lada Markovtsova, John Docherty, Jeffrey Yuan, Ainslie Hatch, Timothy Peters-Strickland
43. **The Test of Psychological Symptoms (TOPS): Development of a New Measure to Optimize Subject Selection in Clinical Trials**
 Brian Rothman, ProPhase, LLC
 Kazu Tatsumi, Jonathan Lam, Anzalee Khan, Mark Opler, Brian Belfi

44. **Symptom Severity and the Generalizability of Antidepressant Efficacy Trials: Changes over the Past 20 Years**
Mark Zimmerman, Brown University
Heather Clark, Matthew Multach, Emily Walsh, Lia Rosenstein, Douglas Gazarian
-  45. **Modulating Tolerability of Acute Painful Stimuli with Transcranial Direct Current Stimulation (tDCS) Targeting Dorsolateral Prefrontal Cortex**
Timothy Mariano, Alpert Medical School, Brown University
Mascha van't Wout, Sarah Garnaat, Steven Rasmussen, Benjamin Greenberg
46. **Antipsychotic Prescribing and Physical Health Monitoring Practices in Patients on a Psychiatric Ward**
Kamini Vasudev, Western University, London, ON, Departments of Psychiatry and Medicine
Rebecca Tudhope, Ajay Prakash
47. **Dextromethorphan/Quinidine for Pseudobulbar Affect in Dementia: Correlation of the CNS-LS PBA Symptom Scale with PBA Episodes, Global, Quality of Life, & Depression Measures in an Open-label Trial**
Andrew Cutler, Florida Clinical Research Center
Rachelle S. Doody, Stephen D'Amico, Paul Shin, Fred Ledon, Charles Yonan, Joao Siffert
48. **Pharmacokinetic Study Comparing Topical, Rectal, and Oral Quetiapine**
Jonathan Leung, Mayo Clinic, Rochester, MN
Sarah Nelson, Cunningham Julie, Thompson Virginia, William Bobo, Simon Kung, Maria Lapid
49. **rTMS Using a Two Coil Electromagnetic Array: Efficacy for Treatment Resistant Major Depressive Disorder**
Scott Aaronson, Sheppard Pratt Health System
Clark Johnson, Gregory Clarke, Linda Carpenter, Paul Holtzheimer, William McDonald, Beth Stannard, Bret Schneider
50. **Increasing Signal Over Noise in MDD Clinical Trials: Rating Improvement after Efficacy Scale Rater Training among Experienced MDD Investigators**
Joan Busner, Penn State College of Medicine, and Bracket Nanco Hefting, Alan Kott, Agathe de Castelneau, Marcela Roy, Gary Sachs



= New Investigator

51. **Depression and Pain Perception: Study on Pain Perception in Subjects with Reported History of Depression**

Bilikis Akindede, Proove Biosciences, Inc.

Tobore Onojighofia, Natasha Anand, Dan Schwarz, John Hubbard

52. **Adjunctive Brexpiprazole (OPC-34712) in Patients with Major Depressive Disorder and Irritability: An Exploratory Study**

Maurizio Fava, Massachusetts General Hospital

François Menard, Charlotte Kampp Davidsen, Ross Baker

53. **Clinical Impact of Switching Antidepressant Pharmacotherapy in Well-treated MDD due to SSRI-Induced Sexual Dysfunction: Comparison between a Direct Switch to Vortioxetine or Escitalopram**

Paula Jacobsen, Takeda Pharmaceuticals

Yinzhong Chen, Wei Zhong, Lambros C. Chrones, Anita H. Clayton

54. **Patterns of Antidepressant Efficacy with Quetiapine XR as Adjunct to Different Ongoing Antidepressants; Exploration of MOA Hypotheses**

Jamie Mullen, AstraZeneca Pharmaceuticals

Catherine Datto, William Pottorf, Scott LaPorte, Charles Liss



55. **Iloperidone Augmentation of SSRIs for Residual Anger and Irritability in Patients with Partially-remitted Major Depressive Disorder: A Placebo-controlled Crossover Study**

Dawn Ionescu, Massachusetts General Hospital

Maurizio Fava, Daniel Kim, Lee Baer, Richard Shelton, Cristina Cusin

56. **Adjunctive Brexpiprazole (opc-34712) in Patients with Major Depressive Disorder and Sleep Disturbances: An Exploratory Study**

Andrew Krystal, Duke Clinical Research Institute and Duke University School of Medicine

Aurelia Mittoux, Peter Meisels, Ross Baker

57. **OPEN BOARD**



58. **Brain Metabolite Abnormalities in Depressed Adolescents**

Kailyn Bradley, Icahn School of Medicine at Mount Sinai

Xiangling Mao, Julia Case, Amira Hanna, Danielle Goldman, Dikoma Shungu, Vilma Gabbay



= New Investigator

59. **The Efficacy of Vortioxetine on Cognitive Dysfunction in Patients with Major Depressive Disorder (MDD) Across Studies**

Christina Olsen, H. Lundbeck A/S

William Jacobson, Søren Lophaven, Henrik Loft



60. **Development and Validation of the Psychotic Depression Assessment Scale (PDAS)**

Søren Dinesen Østergaard, Aarhus University, Denmark, Department of Clinical Medicine

Anthony J. Rothschild, Alastair J. Flint, Benoit H. Mulsant, Ellen M. Whyte, Per Bech, Barnett S. Meyers

61. **The Burden of Treatment Switch in Patients with Major Depression: A US Retrospective Claims Database Analysis**

Vanessa Perez, Takeda Pharmaceuticals International, Inc.

Genevieve Gauthier, Annie Guerin, Clement Francois, Elizabeth Merikle



62. **Neuroinflammation is likely Associated with Depression as Evidenced by Increased PET Radioligand Binding to Translocator Protein**

Erica Richards, National Institute of Mental Health

Paolo Zanotti-Fregonara, Masahiro Fujita, Tessa Walls, Mark Niciu, Minkyung Park, Brittany Jaso, Rodrigo Machado-Vieira, Giacomo Salvatore, Hartmuth Kolb, Carlos Zarate, Robert Innis

63. **Vortioxetine on Overall Patient Functioning in Patients with Major Depressive Disorder**

David Sheehan, University of South Florida College of Medicine

Henrik Loft, Natalya Danchenko, Benoît Rive, Melanie Brignone, Elizabeth Merikle

64. **Psychosocial Relationship Status and Quality as Predictors of Exercise-based Treatment Adherence and Substance Use Outcomes: Results from the STRIDE (CTN-0037) Study**

Joseph Trombello, The University of Texas Southwestern Medical Center, Department of Psychiatry

Thomas Carmody, N. Robrina Walker, Tracy Greer, Chad Rethorst, Madhukar Trivedi


65. **Effect of Adjunctive Brexpiprazole (OPC-34712) on Depressive Symptoms in Patients with Symptoms of Anxious Distress: Results from Post-hoc Analyses**

Emmanuelle Weiller, H. Lundbeck A/S

Roger McIntyre, Peter Zhang, Catherine Weiss




= New Investigator

66. **Incidence, Onset, Duration and Severity of Akathisia with Adjunctive Brexpiprazole (OPC-34712) in Major Depressive Disorder: Analysis of Two Pivotal Studies**
Catherine Weiss, Otsuka Pharmaceutical Development & Commercialization, Inc.
Aleksandar Skuban, Mary Hobart, Peter Zhang, Emmanuelle Weiller
67. **The Future of Subject Registries: Integration or Redundancy?**
Thomas Shiovitz, California Neuroscience Research
Mitchell Efros, Adnan Shawkat, Kerri Weingard, Sabrina Schoneberg
68. **Oral Atypical Antipsychotic Adherence Patterns in Medicaid Patients Diagnosed With Schizophrenia**
Felicia Forma, Otsuka America Pharmaceuticals, Inc.
Joanna MacEwan, Jason Shafrin, Ainslie Hatch, Darius Lakdawalla
69. **Investigation of Antipsychotic Medication Related Cardiometabolic Risk Factors in Patients with Psychotic vs Non-psychotic Disorders in Comparison with a Control Group**
Jayesh Kamath, University of Connecticut Health Center, Department of Psychiatry
Tatjana Dujmovic, Yinghui Duan, Helen Wu, Victoria Scranton
70. **The Cost of Adherence Mismeasurement: A Claims-based Analysis**
Felicia Forma, Otsuka America Pharmaceuticals, Inc.
Jason Shafrin, Ethan Scherer, Ainslie Hatch, Darius Lakdawalla
71. **Antipsychotic Treatment Patterns among Commercially-insured Patients with Schizoaffective Disorder**
Dong Jing Fu, Ortho-McNeil Janssen Scientific Affairs, LLC
Kruti Joshi, Jay Lin, Melissa Lingohr-Smith, Erik Muser
-  72. **Dimensional Traits of Psychosis and Association with Glycine Receptor Polymorphism: An Exploratory Candidate-gene Association Study**
Anvi Vora, Bronx VAMC /Mount Sinai School of Medicine
Larry Siever, Antonia New, Erin Hazlett, Quiaoping Yuan, Zhifeng Zou, Colin Hodgkinson, David Goldman, Panos Roussos, Mercedes Rodriguez-Perez



= New Investigator

73. **The Therapeutic Effect of 1-Methyl-D-Tryptophan, Indoleamine 2,3-Dioxygenase Enzyme Inhibitor, on Ketamine-induced Schizophrenia-like Symptoms in Mice**
Aline Monte, Federal University of Ceara
Tatiane da Silva Araujo, Ana Isabelle Góis Queiroz, Adriano José Maia Chaves Filho, Michel de Jesus Souza Machado, Francisca Taciana Sousa Rodrigues, David Freitas de Lucena, Danielle Macêdo
74. **Effects of Switching to Aripiprazole Once-monthly on Domains of the Heinrichs–Carpenter Quality of Life Scale in Patients with Schizophrenia**
Ross Baker, Otsuka
Cathy Zhao, Brian Johnson, Anna Eramo, Robert McQuade, Anna Duca, Raymond Sanchez, Timothy Peters-Strickland
75. **Effects of Aripiprazole Once-monthly as Long-term Maintenance Treatment in Patients with Schizophrenia**
Ross Baker, Otsuka
Anna-Greta Nylander, Anna Eramo, Robert D. McQuade, Na Jin, Pamela Perry, Brian Johnson, Anna R. Duca, Raymond Sanchez, Timothy Peters-Strickland
-  76. **Tolcapone’s Effect on Neurocognition and Neurophysiological Measures in COMT- Genotyped Healthy Adults**
Savita Bhakta, VA San Diego HealthCare System/ University of California - San Diego
Jo A. Talledo, Erica Hughes, Alexis Alvarez, Brinda K. Rana, Gregory A. Light, Jared W. Young, Neal R. Swerdlow
77. **The Effect of Brexpiprazole (OPC-34712) versus Aripiprazole in Adult Patients with Acute Schizophrenia: Results from a Multicenter, Randomized, Open-label, Flexible-dose, Exploratory Study**
Leslie Citrome, New York Medical College
Ai Ota, Kazuhiro Nagamizu, Pamela Perry, Emmanuelle Weiller, Ross Baker
78. **Efficacy and Safety From a 6-Week Double-blind Trial of Asenapine 2.5 and 5 mg BID in Adults with an Acute Exacerbation of Schizophrenia**
Ian D’Souza, Forest Research Institute (Actavis Group)
Carla Hundt, Ronald Landbloom, Mary Mackle, Xiao Wu, Linda Kelly, Linda Snow-Adami, Roger S. McIntyre, Maju Mathews



= New Investigator

79. **Effects of Aripiprazole Once-monthly in Patients with Schizophrenia Switched from Oral Antipsychotics**
Anna Eramo, Lundbeck
John Kane, Cathy Zhao, Brian Johnson, Ross Baker, Robert McQuade, Anna Duca, Raymond Sanchez, Timothy Peters-Strickland
80. **Metabolic Safety Measures of Aripiprazole Once-monthly in the Long-term Maintenance Treatment of Schizophrenia**
Anna Eramo, Lundbeck
Ross A. Baker, Robert D. McQuade, Na Jin, Pamela Perry, Timothy Peters-Strickland, Brian Johnson, Anna R. Duca, Raymond Sanchez
81. **Effects of Rater Change on Increased PANSS Score Variability**
Alan Kott, Bracket
David Daniel
82. **Comparison of Relapse-prevention Studies of Antipsychotic Medications Developed for Administration Daily, Once per Month, and Once Every 3 Months**
Srihari Gopal, Janssen Research & Development, LLC
Edward Kim, Ibrahim Turkoz, Joris Berwaerts, Larry Alphs
84. **Subjective and Objective Measurement of Medication Adherence in Serious Mental Illness**
Ainslie Hatch, Otsuka America Pharmaceutical, Inc.
Felicia Forma, Shashank Rohatagi, Jonathan Knights
85. **Efficacy of Brexpiprazole (OPC-34712) on PANSS Items and Marder Factor Scores: A Meta-analysis of Two Pivotal Studies in Schizophrenia**
Stephen Marder, Semel Institute at UCLA
Aleksandar Skuban, John Ouyang, Catherine Weiss, Emmanuelle Weiller
86. **Scientific Brain Training Programs on Cognition, Social Cognition and Functioning: Comparison of Cognitive Remediation Programs in Severe Mental Illness**
Anzalee Khan, ProPhase, LLC
Jean-Pierre Lindenmayer, Susan McGurk

87. **Secondary Effectiveness Outcomes in QUALIFY, A Head-to-Head Clinical Study of Aripiprazole Once-monthly and Paliperidone Palmitate in Schizophrenia**
Dieter Naber, University Medical Center Hamburg-Eppendorf
Karina Hansen, Carlos Forray, Ross Baker, Christophe Sapin, Maud Beillat, Timothy Peters-Strickland, Anna-Greta Nylander, Peter Hertel, Henrik Steen Anderson, Anna Eramo, Jean-Yves Loze, Steven Potkin
88. **Effect of Aripiprazole Lauroxil on Metabolic and Endocrine Profiles, and Related Safety Considerations in Acute Schizophrenia**
Henry Nasrallah, Saint Louis University School of Medicine
John Newcomer, Srdjan Stankovic, Robert Risinger, Yangchun Du, Jacqueline Zummo, Jennifer Layne, Anjana Bose, Bernard Silverman, Elliot Ehrlich
89. **The Effect of Brexpiprazole (OPC-34712) in Adult Outpatients with Early-episode Schizophrenia: An Exploratory Study**
Ashok Malla, McGill University, Douglas Mental Health University Institute
Kensaku Sugaya, Pamela Perry, Kazuhiro Nagamizu, Emmanuelle Weiller, Ross Baker
90. **Iloperidone as a Long-term Maintenance Treatment: Results from a Placebo-controlled Randomized Withdrawal Study**
Peter Weiden, University of Illinois at Chicago
Raymond Manning, Linda Mancione, Jackie Han, Saeeduddin Ahmed, Rosarelis Torres, J. Michael Ryan, Curt Wolfgang
91. **Prior Hospitalization and Treatment Effect Size in Schizophrenia: A Moderator Analysis**
Steven Potkin, University of California - Irvine, School of Medicine
Antony Loebel, Cynthia Siu, Josephine Cucchiaro, Andrei Pikalov
92. **The National Pregnancy Registry for Atypical Antipsychotics: Effects of Fetal Exposure on Risk for Major Malformations**
Lee Cohen, Massachusetts General Hospital
Adele Viguera, Kathryn McInerney, Danna Moustafa, Samantha Marfurt, Alexandra Sosinsky, Molly Kwiatkowski, Shannon Murphy, Adriann Farrell, David Chitayat, Sonia Hernández-Díaz



93.

Major Depressive Disorder and the Role of Anxiety in Establishing Biomarkers for Clinical Care using fMRI of Emotion Conflict Regulation: Results from the EMBARC Study

Crystal Cooper, UT Southwestern Medical Center

Brian Patenaude, Henry Chase, Tsafir Greenberg, Thomas Carmody, Maurizio Fava, Patrick McGrath, Melvin McInnis, Myrna Weissman, Maria Oquendo, Ramin Parsey, Mary Phillips, Amit Etkin, Madhukar Trivedi

94.

Do Psychiatric Inpatients Who Report Aggression and Impulsivity also Score Higher on the Sheehan-Suicidality Tracking Scale?

Ahmad Hameed, Penn State College of Medicine, Milton S. Hershey Medical Center

Michael Mitchell, Vankatesh Krishnamurthy, Eric Youngstrom, Roger Meyer, Alan Gelenberg, Amanda White

95.

Efficacy and Safety of Brexpiprazole (OPC-34712) as Adjunctive Treatment in Major Depressive Disorder: Meta-analysis of Two Pivotal Studies

Michael E. Thase, Perelman School of Medicine at the University of Pennsylvania

Peter Zhang, Aleksandar Skuban, Emmanuelle Weiller, Catherine Weiss, Hans Eriksson

96.

The Efficacy of Vortioxetine in the Treatment of Patients with MDD in Short-term Placebo-controlled Studies: A Meta-analysis of 11 Studies

Michael E. Thase, Perelman School of Medicine at the University of Pennsylvania

Henrik Loft, Atul R. Mahableshwarkar, Ioana Florea, Eduard Vieta



= New Investigator

Wednesday, June 24, 2015

Poster Session II

1. **No Food Effect for a Novel Oral Disintegrating Tablet Formulation of Extended-release Methylphenidate for the Treatment of ADHD**
Russ McMahan, Neos Therapeutics, Inc.
Mark Tengler, Jeffrey Stark, Carolyn Sikes
2. **The Controlled-release Properties and Exposure Levels of a Novel Orally Disintegrating Tablet Formulation of Amphetamine for Treatment of ADHD are Maintained in the Presence of Alcohol**
Carolyn Sikes, NEOS Therapeutics, Inc.
Sherilyn Adcock, Jeffrey Stark, Russ McMahan, Mark Tengler
3. **Dopamine Transporter Gene (DAT1) Dopamine Receptor Gene (DRDR4), and Response to Methylphenidate and Atomoxetine Treatment in ADHD Youth**
Mark Stein, University of Washington
Thomas Hildebrandt, Emily Olsen, Edwin Cook, Jr., Jeff Bishop, Jeffrey Newcorn
4. **Does the Presence of Attention Deficit Hyperactivity Disorder Predict Treatment Failure in Patients Diagnosed with Major Depressive Disorder Prescribed SSRIs?**
Tia Sternat, Anxiety Disorders Association of America
Munira Mohamed, Leena Anand, Melissa Furtado, Irvin Epstein, Isaac Szpindel, Catherine Cameron, Martin Katzman
5. **Review of Oral Cocaine Alkaloid as Agonist Therapy: A Proposal Originated and Applied in Perú for Smoked Cocaine (Coca Paste) Dependence**
Teobaldo Llosa, Cocamedica Research Institute
6. **Stress-related Cognitive Deficits: Implications for Anxiety Disorders**
J.H. Blaise, Trinity College
7. **Differential Olfactory Sensitivity in Combat Veterans with and without PTSD**
Bernadette Cortese, Medical University of South Carolina Department of Psychiatry & Behavioral Sciences
Kimberly Leslie, Thomas W. Uhde

8. **Post Hoc Analyses of Anxiety Measures in Adult Patients with Generalized Anxiety Disorder Treated with Vilazodone**

Arifulla Khan, Northwest Clinical Research Center
Suresh Durgam, Xiongwen Tang, Adam Ruth, Maju Mathews, Carl Gommoll



9. **Trauma and PTSD Predict Violence in Urban Civilians**

Jeff Sanders, Emory University School of Medicine, Department of Psychiatry
Cindy Gillikin, Kerry Ressler

10. **Combined Neurocognitive and EEG Biomarkers to Assess Effects of CNS Depressants and Stimulants**

Stephanie Korszen, Advanced Brain Monitoring
Robin Johnson, Shani Waninger, Aaron Kemp, Maja Stikic, Chris Berka

11. **Auditory P300 in Patients with Major Depression Treated with Quetiapine (Seroquel®): A Preliminary Study**

Ulises Montero, Instituto Mexicano del Seguro Social
Bernardo Pliego, Irma Corlay, Josefina Ricardo, Gloria Otero

12. **Association of Obesity and Inflammatory Marker Levels with Treatment Outcome from a Study of Adjunctive L-Methylfolate Calcium in MDD Patients with Inadequate Response to SSRIs**

Richard Shelton, University of Alabama at Birmingham
Michael Pencina, Lori Barrentine, George Papakostas, Maurizio Fava

13. **Implementing Pharmacogenetic Testing into a Psychiatry Residency Training Clinic: A Quality Improvement Project**

Bernadette Stevenson, Advocate Lutheran General Hospital

14. **Identifying Psychiatric Disorders in Young Adults in Primary and Secondary Care: How Do Bipolar Disorders Differ? Results from a 10-Year Study**

Andrée Daigneault, McGill University Faculty of Medicine
Catherine Duclos, Sybille Saury, Jean Paquet, Serge Beaulieu

15. **Lurasidone in the Long-term Treatment of Patients with Bipolar I Disorder: Responder and Remitter Status During a 24-Week Open-label Extension Study**

Terence Ketter, Stanford University School of Medicine
Joyce Tsai, Robert Silva, Hans Kroger, Josephine Cucchiari, Antony Loebel



= New Investigator

16. **Categorical Improvement Across Mania Symptoms: Pooled Analyses of Cariprazine Phase II/III Trials**
Suresh Durgam, Forest Research Institute, a Subsidiary of Actavis PLC
Stephen Zukin, Kaifeng Lu, Adam Ruth, Marc Debelles
17. **Effect of Lurasidone on Metabolic Parameters in Patients with Bipolar Depression**
John W. Newcomer, Florida Atlantic University
Joyce Tsai, Andrei Pikalov, Hans Kroger, Josephine Cucchiari, Antony Loebel
18. **Pharmacological Treatment of Depression in Children and Adolescents: Switching vs. Augmenting**
Zainab Zia, University of Texas at Southwestern Dallas
Zohra Chahal, Taryn Mayes, Catherine Karni, Graham Emslie
19. **What Can Data Monitoring Tell Us About Where to Focus Efforts to Remediate Problematic Scoring of the Positive and Negative Syndrome Scale?**
Nina Engelhardt, Cronos Clinical Consulting Services
Kristy Wolanski, Francisco Burger, Matt Masotti, Christian Yavorsky, Guillermo DiClemente
20. **Psychometric Properties of the Dynamic Social Cognition Battery (DSCB) in Patients with Severe Mental Illness**
Anzalee Khan, ProPhase, LLC
Mark Opler, Brian Rothman, Luka Lucic
21. **Design of the Schizophrenia Disease Recovery Evaluation and Modification (DREaM) Study**
Dong Jing Fu, Ortho-McNeil Janssen Scientific Affairs, LLC
Ibrahim Turkoz, Larry Alphs
22. **A Novel, Disease-specific Scoring Algorithm for the Clinical Global Impression Scale (CGI) in Down Syndrome**
Brian Rothman, ProPhase, LLC
Michael Aman, Mark Opler, Anzalee Khan, Xavier Liogier D'ardhuy
23. **Regional Distribution of Scoring Errors in Rating the Clinical Global Impression Scale in Global Schizophrenia Clinical Trials**
Alan Kott, Bracket

24. **The First Study: Family Intervention in Recently Diagnosed Patients with Schizophrenia**
 Branislav Mancevski, Janssen Scientific Affairs, LLC
 Larry Alphs, Carmela Benson, Kimberly Cheshire-Kinney, Lian Mao, Edward Kim

25. **Who is Participating in Clinical Trials?**
 Deborah Renner, Clinical Neuroscience Solutions, Inc.
 Rebecca Hummel, Shaina Shepherd, Jeffrey Rommel, Josephine Wheeler

26. **A New Platform to Improve Quality of PANSS and MADRS Administration**
 Janet Williams, MedAvante
 Barbara Echevarria, Douglas Osman, Lori Garzio

27. **Increasing Usage of Sedative Antidepressants in Long-term Care Homes Among Elderly with Dementia: A Population-based Time-series Analysis**
 Akshya Vasudev, Western University
 Salimah Shariff, Kuan Liu, Amer Burhan, Nathan Herrmann, Sean Leonard, Muhammad Mamdani

28. **Predictors of Response to Antipsychotic Treatment in Behavioral and Psychological Symptoms with Dementia - Analysis of the CATIE-AD Data**
 Kazunari Yoshida, Keio University School of Medicine, Department of Neuropsychiatry
 Takefumi Suzuki, Barry Lebowitz, Suzanne Reeves, Robert Howard, Masaru Mimura, Hiroyuki Uchida

-  29. **Nocturnal Wakefulness is Associated with Next-day Suicidal Ideation in Major Depression and Bipolar Disorder: A Proposed Warning Sign and Acute Indicator of Risk**
 Elizabeth Ballard, National Institute of Mental Health
 Jennifer Vande Voort, Rebecca Bernert, David Luckenbaugh, Erica Richards, Mark Niciu, Maura Furey, Wallace Duncan, Carlos Zarate

30. **Family Cultural Conflict, Major Depressive Episode, and Mental Health Service Utilization Among Latinos**
 Joanna Barreras, University of California, Los Angeles



= New Investigator

31. **Adjunctive Brexpiprazole (OPC-34712) in Patients with Major Depressive Disorder and Anxiety Symptoms: An Exploratory Study**
Lori Davis, Veterans Affairs Medical Center
Ai Ota, Pamela Perry, Kana Tsuneyoshi, Emmanuelle Weiller, Ross Baker



32. **The Role of the Kynurenine Pathway in Suicidality in Adolescent Major Depressive Disorder**
Kailyn Bradley, Icahn School of Medicine at Mount Sinai
Julia Case, Omar Khan, Thomas Ricart, Amira Hanna, Carmen Alonso, Vilma Gabbay

33. **Clinical and Pharmacogenetic Outcomes of a Double-blind Antidepressant Treatment Study in Mexican-Americans**
Ma-Li Wong, SAHMRI - Flinders
Chuanhui Dong, Deborah L. Flores, Monika Ehrhart-Bornstein, Stefan R. Bornstein, Mauricio Arcos-Burgos, Julio Licinio



34. **Association between Stigma and Depression Outcomes among Chinese American Immigrants in a Primary Care Setting**
Justin Chen, Massachusetts General Hospital & Harvard Medical School
Nhi-Ha Trinh, Benjamin Shapero, Trina Chang, Albert Yeung

35. **The Effect of Adjunctive Brexpiprazole (OPC-34712) on Depressive Symptoms in Patients with Irritability: Results from Post-hoc Analyses**
Maurizio Fava, Massachusetts General Hospital
Emmanuelle Weiller, Peter Zhang, Catherine Weiss

36. **Combinations of Buprenorphine and Samidorphan Modulate Glutamate and GABA Transmission in the Medial Prefrontal Cortex and Ventral Hippocampus of Male Wistar Rats**
David Eyerman, Alkermes, Inc.
Helen Rowley, Jacobi Cunningham, David Heal, Reginald Dean, Daniel Deaver

37. **Comparative Assessment of Vortioxetine or Escitalopram on the Symptoms of TSED in Well-treated MDD Patients Previously Treated with SSRIs**
Anita Clayton, University of Virginia
Paula L. Jacobsen, Yinzhong Chen, Wei Zhong, Lambros C. Chrones, Atul R. Mahableshwarkar



= New Investigator

38. **Levomilnacipran ER Treatment in Adult MDD Patients in a Recurrent Depressive Episode or in the First Depressive Episode**
Susan Kornstein, Virginia Commonwealth University
Carl Gommoll, Chen Chen

39. **Efficacy and Safety of Cariprazine as Adjunctive Therapy in Major Depressive Disorder: A Double-blind, Randomized, Placebo-controlled Study**
Willie Earley, Forest Research Institute
Maurizio Fava, Suresh Durgam, Hua Guo, György Németh, István Laszlovszky

40. **The Association between School Bullying and Depression: Evidence from TwinssCanChina Study**
Lu Hua Chen, University of Hong Kong
Francesca Cotier, Winifred Mark, Jim van Os, Timothea Touloupoulou

41. **The Safety and Tolerability of Vortioxetine in Treating Adults with Major Depressive Disorder for 52 Weeks with Open-label Treatment**
Atul Mahableshwarkar, Takeda Global R&D
Lambros C. Chrones, William Palo, Jørgen Matz

42. **Patterns of Improvement in Patients with Acute Depressive Episodes of Bipolar I Disorder and Bipolar II Disorder**
Jamie Mullen, AstraZeneca Pharmaceuticals
Catherine Datto, William Pottorf, Scott LaPorte, Charles Liss


43. **Providing Further Details on the Experience of Somnolence for Patients with Acute Depressive Episodes Treated with Quetiapine XR**
Jamie Mullen, AstraZeneca Pharmaceuticals
Omaira Meléndez Nesbit, Catherine Datto, William Pottorf, Scott LaPorte, Charles Liss

44. **Methylphenidate Augmentation for Treatment Resistant Depression in an Elderly Patient with Meningioma**
Subramoniam Madhusoodanan, St. Johns Episcopal Hospital
Johanna Landinez

45. **The Metabolic Tolerability Profile of Adjunct Brexpiprazole (OPC-34712) in Major Depressive Disorder**
J. Craig Nelson, University of California San Francisco
Aleksandar Skuban, Mary Hobart, Peter Zhang, Catherine Weiss, Emmanuelle Weiller

46. **Delay in Use of Adjunct Atypical Antipsychotic Treatment for Major Depressive Disorder is Associated with Higher Physician Office Visits and Costs**
Susan Legacy, Otsuka America Pharmaceutical, Inc.
Donna McMorro, Ruth Duffy, Siddhesh A. Kamat, Stephen Johnston, Alice Guiraud-Diawara, Anna Eramo, Aneta Fornal, Rajnish Mago
47. **CERC-301: An Oral NR2B Specific NMDA Antagonist being Developed for the Treatment of Major Depressive Disorder with Potential for a Rapid Onset of Antidepressant Effect**
Blake Paterson, Cerecor, Inc.
Heather Fraser, Reza Mazhari, Rachel Garner, Maurizio Fava, Michael Detke, Chao Wang, Debra Kelsh, Bradley Vince, Larry Ereshefsky, Richard Shelton, Michael E. Thase, Madhukar Trivedi
48. **Major Depressive Disorder with Mixed Features: Clinical Characteristics of Patients Entered in a Multiregional Placebo-controlled Study**
Jo Pendergrass, Clintara, LLC
Steven Targum, Trisha Suppes, Sang Lee, Robert Silva, Josephine Cucchiaro, Antony Loebel
49. **Relative Efficacy and Tolerability of Vortioxetine Versus Commonly Used Antidepressants for Major Depressive Disorder: A Meta-regression of Clinical Trials**
Vanessa Perez, Takeda Pharmaceuticals International, Inc.
Natalya Danchenko, Melanie Brignone, Benoit Rive, Larry Ereshefsky, Clement Francois, Elizabeth Merikle
50. **OPEN BOARD**
51. **Deuterium-modified Dextromethorphan and Ultra Low-dose Quinidine (AVP-786; d6 DM/Q): Results of a Phase 1 Sequential Drug Interaction Trial with Paroxetine and Duloxetine in Healthy Subjects**
Joao Siffert, Avanir Pharmaceuticals, Inc.
Nadine Knowles, Laura Pope
52. **Motivation/Energy, Functional Impairment, and Functional Health in Adults with MDD Treated with Levomilnacipran ER**
Michael E. Thase, Perelman School of Medicine at the University of Pennsylvania
Carl Gommoll, Changzheng Chen, Angelo Sambunaris

53. **Switching from Inadequate Adjunctive Treatment Options to Brexpiprazole Adjunctive to Antidepressant: An Open-label Study on the Effects on Depressive Symptoms and Cognitive and Physical Functioning**
Madhukar Trivedi, UT Southwestern Medical Center
Emmanuelle Weiller, Takao Okame, Pamela Perry, Yuki Matsushima, Ross Baker
54. **Adjunctive Brexpiprazole (OPC-34712) in Young Patients with MDD who are Working or at School: An Exploratory Study**
Richard Weisler, Duke University Medical Center and University of North Carolina at Chapel Hill
Ai Ota, Pamela Perry, Kana Tsuneyoshi, Ross Baker, Emmanuelle Weiller, David V. Sheehan
55. **Pharmacotherapy Relapse Prevention in Body Dysmorphic Disorder: A Double-blind, Placebo-controlled Trial**
Katharine Phillips, Rhode Island Hospital/Brown University
Robert Stout, Darin Dougherty, William Menard, Aparna Keshaviah, Sabine Wilhelm
56. **Preclinical Evidence Showing that Lisdexamfetamine (LDX) Prevents Compulsive and Perseverative Behaviour Associated with Binge Eating**
Pete Hutson, Shire
Steve Vickers, Simon Goddard, Richard Brammer, David Heal
57. **Time Course of the Effects of Lisdexamfetamine Dimesylate in Two Phase 3 Randomized, Double-blind, Placebo-controlled Trials in Adults with Binge Eating Disorder**
Susan McElroy, Lindner Center of HOPE/University of Cincinnati College of Medicine
James Hudson, Maria Gasior, Barry Herman, Jana Radewonuk, Denise Wilfley, Joan Busner
58. **Adherence to Treatment with Antipsychotic Medications among Patients with Schizophrenia, Major Depressive Disorder, or Bipolar Disorder**
Robert Millet, Carolina Behavioral Care
Michael DeGeorge, Patricia Woster, Mancia Ko, Thomas Smith


59. **Epidemiology and Economic Burden of Serotonin Syndrome with Concomitant Use of Serotonergic Agents in the U.S. Clinical Practice**
Charles Nguyen, UC Irvine
Lin Xie, Stephanie Alley, Onur Baser, Zhixiao Wang
60. **Effects of Lisdexamfetamine Dimesylate on Functional Impairment Measured on the Sheehan Disability Scale in Adults with Moderate to Severe Binge Eating Disorder: Results from Two Placebo-controlled Trial**
David Sheehan, University of South Florida College of Medicine
Maria Gasior, Susan McElroy, Jana Radewonuk, Barry Herman, Manjiri Pawaskar, James Hudson
61. **The Neuroprotective Effect of Erythrina Velutina Standardised Extract on Amino Acid Levels in Mouse Hippocampus**
Aline Monte, Federal University of Ceara
Francisca Taciana Sousa Rodrigues, Ana Isabelle de Góis Queiroz, Tatiane da Silva Araujo, Marcos Romário Matos de Souza, Biatriz Bezerra Castelo Cardoso, Carolina de Paiva Farias, David Freitas de Lucena, Silvânia Maria Mendes Vasconcelos, Danielle Macêdo
62. **Evaluation of Cytochrome P450 Phenotypes and Potential Implications in the Treatment of Serious Mental Illness**
Patricia Woster, Ingenuity Health
Michael DeGeorge, Mancia Ko, Stewart Holt, Zengliu Su, Thomas Smith
-  63. **Weight Change and Cardiometabolic Risk with Antipsychotic Polypharmacy: Meta-analysis Showing Improved Outcomes with Certain Aripiprazole Combinations**
Vishesh Agarwal, Einstein Medical Center
Christoph Correll
64. **Comparative Posological Results for 3 Formulations of Paliperidone Used in the Management of Patients with Psychotic Disorders**
Larry Alphs, Janssen
Jennifer Kern Sliwa



= New Investigator

65. **Effects of Bitopertin on Biomarker Measures of Cognitive Dysfunction in Adults with Schizophrenia and Schizoaffective Disorder: Results from a Ph1b, Double Blind, Placebo Controlled Parallel Arm Study**
Daniel Da Costa, F. Hoffmann-La Roche, Ltd., Pharmaceutical Division
Daniel Umbricht, Eriene Youssef, Daniel Javitt, Paulo Fontoura, Luca Santarelli
66. **Efficacy of Cariprazine Versus Placebo across Schizophrenia Symptom Domains: Pooled Analyses from 3 Phase II/III Trials**
Willie Earley, Forest Research Institute
W. Wolfgang Fleischhacker, Stephen Marder, Kaifeng Lu, Dayong Li, Paul Ferguson, György Németh, István Laszlovszky, Suresh Durgam
67. **Open Board**
68. **Safety, Tolerability, and Pharmacokinetics of a Novel PDE10A Inhibitor -TAK-063 - Following Multiple Dosing in Subjects with Stable Schizophrenia and Healthy Japanese Subjects**
Paul Goldsmith, Takeda Pharmaceuticals International, Inc.
John Affinito, Tom Macek, Max Tsai, Jinhui Xie, Lev Gertsik
69. **An Antipsychotic Treatment that Delivers Paliperidone Provides a 3-Month Dosing Interval: An Assessment of a Relapse-prevention Trial**
Srihari Gopal, Janssen Research & Development, LLC
Larry Alphs, Joris Berwaerts, Isaac Nuamah
70. **Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: A Randomized, Double-blind, Placebo-controlled Study**
Mary Hobart, Otsuka Pharmaceutical Development and Commercialization, Inc.
John Ouyang, Andy Forbes, Stephanie Pfister, Robert D. McQuade, William H. Carson, Raymond Sanchez, Margaretta Nyilas, Emmanuelle Weiller, W. Wolfgang Fleischhacker
71. **Longitudinal Analysis of the Individual Placebo Response from Double-blind Clinical Studies Using the MATRICS Consensus Cognitive Battery (MCCB) in Cognitive Impairment Associated with Schizophrenia**
Richard Keefe, Duke University Medical Center
Timothy Nicholas, Vicki Davis, Ye Tan, Nicholas Demartinis, Jessica Mancuso, Francois Gaudreault, Danny Chen, Ilise Lombardo, Brendon Binneman

72. **Differential Activation of Immune/ Inflammatory Response Related Co-expression Modules in the Hippocampus across the Major Psychiatric Disorders**
Sanghyeon Kim, SMRI
Maree Webster
73. **Long-acting Injectable vs. Oral Antipsychotics for Hospitalization Prevention in Schizophrenia: A Systematic Review and Meta-analysis of Cohort Studies**
Taishiro Kishimoto, Keio University School of Medicine
Katsuhiko Hagi, Masahiro Nitta, Stefan Leucht, John M. Kane, Christoph Correll
74. **Role of FGF14 in the Inhibitory Circuitry Underlying Cognitive Processing**
Fernanda Laezza, UTMB
Tahani Alshammari, Musaad Alshammari, Miroslav Nenov, Eriola Hoxha, Thomas James, Marco Cambiaghi, Benedetto Sacchetti, Filippo Tempia
75. **Lurasidone Treatment Response in Patients with Schizophrenia Assessed Using the DSM-5 Dimensions of Psychosis Severity Scale**
Antony Loebel, Sunovion Pharmaceuticals, Inc.
Nina Schooler, Cynthia Siu, Josephine Cucchiaro, Andrei Pikalov, Robert Goldman, Fred Grossman
76. **Optimizing Response to Lurasidone in Patients with Acute Schizophrenia: A Randomized, Double-blind, Placebo-controlled Study of Dosing Regimens**
Antony Loebel, Sunovion Pharmaceuticals, Inc.
Robert Silva, Robert Goldman, Kei Watabe, Josephine Cucchiaro, John Kane
77. **Association of Cardiovascular Risk Factors with Cognitive Impairment in Individuals with Schizophrenia- A Systematic Review**
Satyajit Mohite, The University of Texas Health Science Center at Houston
Ajay Parsaik, Olusegun Popoola, Marie-Louise Tangu, Olaoluwa Okusaga

78. **Incidence, Onset, Duration and Severity of Akathisia with Brexpiprazole (Opc-34712) in Acute Schizophrenia: A Pooled Analysis of Two Pivotal Studies**
 Anna Eramo, Lundbeck
 Aleksandar Skuban, John Ouyang, Mary Hobart, Catherine Weiss, Emmanuelle Weiller
79. **Effects of Lurasidone on Hostility in Patients with an Acute Exacerbation of Schizophrenia: A Pooled Analysis of Five Short-term Studies**
 Andrei Pikalov, Sunovion Pharmaceuticals, Inc.
 Leslie Citrome, Michael Tocco, Jay Hsu, Antony Loebel
80. **Effect of Lurasidone on Prosocial Functioning in Patients with Schizophrenia: A Pooled Analysis of Five Short-term, Placebo-controlled Studies**
 Andrei Pikalov, Sunovion Pharmaceuticals, Inc.
 Michael Tocco, Hanzhe Zheng, Josephine Cucchiaro, Antony Loebel
81. **Metabolic Syndrome Prevalence in Patients with Schizophrenia Receiving Short-term Treatment with Lurasidone, Olanzapine, and Quetiapine XR: A Pooled Analysis**
 Andrei Pikalov, Sunovion Pharmaceuticals, Inc.
 John Newcomer, Michael Tocco, Hanzhe Zheng, Josephine Cucchiaro, Antony Loebel
82. **A Meta-analysis of Placebo-controlled Trials of Omega-3 Fatty Acid Augmentation in Schizophrenia: Possible Stage-specific Effects**
 Henry Nasrallah, Saint Louis University School of Medicine
 Alexander Chen, John Chibnall
-  83. **Antipsychotic Dose Increase or Stay in Non-responders with Schizophrenia: A Double-blind Randomized Controlled Trial**
 Hitoshi Sakurai, Keio University School of Medicine, Department of Neuropsychiatry
 Takefumi Suzuki, Shitij Kapur, Hiroyuki Uchida
84. **Open Board**
85. **Safety, Tolerability and Pharmacokinetics of TAK-063, a PDE10A Inhibitor, after a Single Dose in Healthy Japanese and Non-Japanese Subjects**
 Max Tsai, Takeda Pharmaceuticals International, Inc.
 Tom Macek, Lambros Chrones, Jinhui Xie, Hakop Gevorkyan



= New Investigator

86. **Deltoid Injection of Aripiprazole Once-monthly in the Treatment of Schizophrenia**
Timothy Peters-Strickland, Otsuka Pharmaceutical
Arash Raoufinia, Anna-Greta Nylander, Ross A. Baker, Anna Eramo, Na Jin, Robert D. McQuade, Peter Hertel, Frank Larsen
87. **Advancing the Clinical Development of ITI-007: A Novel Investigational Treatment for Schizophrenia, Bipolar Depression and Behavioral Disturbances in Dementia**
Kimberly Vanover, Intra-Cellular Therapies, Inc.
Robert E. Davis, Cedric O’Gorman, Jelena Saillard, Michal Weingart, Sharon Mates
88. **Effect of Aripiprazole Lauroxil on Personal and Social Functioning and Health-related Quality of Life among Patients with Schizophrenia**
Peter Weiden, University of Illinois at Chicago
Srdjan Stankovic, Robert Risinger, Yangchun Du, Jacqueline Zummo, Jennifer Layne, Anjana Bose, Bernard Silverman, Elliot Ehrich
89. **The Metabolic Tolerability Profile of Brexpiprazole (OPC-34712) in Acute Schizophrenia**
Catherine Weiss, Otsuka Pharmaceutical Development & Commercialization, Inc.
Aleksandar Skuban, Mary Hobart, Peter Zhang, Emmanuelle Weiller
90. **Tolerability and Response to Low-dose Gabapentin among Midlife Women with Hot Flashes and Insomnia**
Lee Cohen, Massachusetts General Hospital
Marlene Freeman, Katherine A. Guthrie, Betty Wang, Abigail Davies, Danna Moustafa, David Wolfe, Geena Athappilly, Thania Galvan, Hadine Joffe
91. **Phase IIa Study of a Proprietary Combination of Bupropion and Trazodone for Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women: Novel Responder and Remitter Results**
Robert Pyke, S1 Biopharma, Inc.
92. **Effect of Lurasidone Dose on Cognitive Impairment in Patients with Schizophrenia: Post-hoc Analysis of a Long-term, Double-blind Continuation Study**
Philip Harvey, Miller School of Medicine, University of Miami
Cynthia Siu, Masaaki Ogasa, Antony Loebel

93. **Role of BMI as Risk or Protective Factor for Suicidality among Adult Psychiatric Inpatients**

Amhed Hameed, Penn State Milton S. Hershey Medical Center
Michael Mitchell, Venkatesh Krishnamurthy, Eric Youngstrom, Roger Meyer, Alan Gelenberg, Amanda White

94. **Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-blind, Placebo-controlled, Proof-Of-Concept Trial in Adults**

Robert Goldman, Sunovion
Kenneth S. Koblan, Kaushik Sarma, Fengbin Jin, Robert Goldman, Scott H. Kollins, Antony Loebel



95. **Switching to Clozapine Using Immediate vs. Gradual Antipsychotic Discontinuation: A Pilot, Double-blind, Randomized Controlled Trial**

Hiroyoshi Takeuchi, Centre for Addiction and Mental Health, University of Toronto
Jimmy Lee, Gagan Fervaha, George Foussias, Ofer Agid, Gary Remington



96. **The Relationship between Insight into Illness and Cognition in Schizophrenia across the Adult Lifespan**

Hiroyoshi Takeuchi, Centre for Addiction and Mental Health, University of Toronto
Aristotle Voineskos, Mahesh Menon, Ariel Graff-Guerrero, Bruce Pollock, David Mamo, Benoit H. Mulsant, Tarek Rajji



= New Investigator

Aaronson, Scott	79	Berka, Chris	88
Abramson, Ruth K.	77	Bernert, Rebecca	90
Achtyes, Eric	51	Bertazzo, Antonella	75
Adcock, Sherilyn	87	Berwaerts, Joris	84, 96
Adler, Caleb	76	Beversdorf, David	42
Affinito, John	96	Beyer, Ulrich	73
Agarwal, Vishesh	7, 95	Bhakta, Savita	7, 83
Agid, Ofer	100	Binneman, Brendon	96
Ahmed, Saeeduddin	85	Bishnoi, Ram	7, 53
Akindele, Bilikis	80	Bishop, Jeff	87
Allen, Michael	38	Blader, Joseph	31
Alley, Stephanie	95	Blaise, J.H.	87
Alonso, Carmen	91	Blier, Pierre	44
Alphs, Larry	65, 77, 84, 89, 90, 95, 96	Blom, Thomas	76
Alshammari, Musaad	97	Boak, Lauren	73
Alshammari, Tahani	97	Bobo, William	79
Alvarez, Alexis	83	Bolinaga, Jorge	75
Aman, Michael	89	Bornstein, Stefan R.	91
Anand, Leena	87	Bose, Anjana	73, 85, 99
Anand, Natasha	80	Bradley, Catharine	77
Anderson, Henrik Steen	85	Bradley, Kailyn	7, 80, 91
Araujo, Tatiane da Silva	76, 83, 95	Brady, Chris	69
Arcos-Burgos, Mauricio	91	Brammer, Richard	94
Arnsten, Julia	74	Brignone, Melanie	81, 93
Athappilly, Geena	99	Bunker, Mark	23, 31
Atkins, Alexandra	52	Burch, Ronald	43, 74
Averina, Olga	75	Burgdorf, Jeffrey	74
Avrumson, Rolana	78	Burger, Francisco	89
Baer, Lee	80	Burghardt, Paul	49
Baker, Ross	54, 80, 83, 84, 85, 91, 94, 99	Burhan, Amer	90
Baldwin, Kim	78	Burns, Trudy	74
Ballard, Elizabeth	7, 90	Busner, Joan	79, 94
Banken, Ludger	73	Calarge, Chadi	74
Barrentine, Lori	88	Cambiaghi, Marco	97
Barreras, Joanna	90	Cameron, Catherine	87
Baser, Onur	95	Canuso, Carla	77
Bastin, Lee	74	Carbo, Melissa	78
Bauer, Isabelle	7, 53	Cardoso, Biatriz Bezerra	95
Beaulieu, Serge	88	Carmody, Thomas	81, 86
Bech, Per	81	Carpenter, Laura	77
Beillat, Maud	85	Carpenter, Linda	79
Belanoff, Joseph	41	Carson, William H.	96
Belfi, Brian	78	Case, Julia	80, 91
Belopolskay, Marina	75	Chacko, Anil	50
Benson, Carmela	90	Chahal, Zohra	89
Bera, Rimal	65	Chang, Christina	70
		Chang, Trina	91
		Chase, Henry	86

Chen, Alexander	98	Daniely, Yaron	73
Chen, Changzheng	93	D'ardhuy, Xavier Liogier	89
Chen, Chen	92	Datto, Catherine	80, 92
Chen, Danny	96	Davidson, Charlotte Kamp	80
Chen, Justin	7, 91	Davies, Abigail	99
Chen, Lu Hua	92	Davis, Lori	20, 23, 31, 91
Chen, Yinzong	80, 91	Davis, Robert E.	99
Chengappa, K.N. Roy	6	Davis, Vicki	96
Cheshire-Kinney, Kimberly	90	Dawson, Geraldine	12, 60
Chibnall, John	98	Dean, Reginald	91
Childress, Ann	49	Deaver, Daniel	73, 91
Chitayat, David	85	Debelle, Marc	89
Chiu, Yu-Yuan	77	de Castelnau, Agathe	79
Chronos, Lambros	80, 91, 92, 98	Deckersbach, Thilo	21
Citrome, Leslie	21, 24, 38, 55, 83, 98	DeGeorge, Michael	94, 95
Clark, Crystal	56	DeGiorgio, Christopher	73
Clark, Heather	79	DelBello, Melissa	76
Clarke, Gregory	79	Deligiannidis, Kristina	24
Clayton, Anita	44, 73, 80, 91	De Lucena, David	50, 76, 83, 95
Cohen, Elan	78	Demartinis, Nicholas	96
Cohen, Lawrence	21	Deptula, Dennis	73
Cohen, Lee	85, 99	de Quevedo, João	32, 33, 50, 70, 76
Comai, Stefano	7, 75	de Souza, Marcos Romário	95
Connor, Gary	74	Detke, Michael	43, 74, 93
Cook, Edwin	87	DeVane, Lindsay	77
Cook, Ian	43, 73	DiClemente, Guillermo	89
Cooper, Crystal	7, 86	Diniz, Breno Satler	33, 70
Corlay, Irma	88	DiPetrillo, Lauren	54
Correll, Christoph	21, 23, 24, 31, 95, 97	Dirks, Bryan L.	20
Cortese, Bernadette	87	Docherty, John	78
Côté, Gilles	75	Dong, Chuanhui	91
Cotier, Francesca	92	Doody, Rachelle S.	79
Coulson, Alisha	78	Dougherty, Darin	94
Cucchiaro, Josephine	52, 76, 77, 85, 88, 89, 93, 97, 98	Drevets, Wayne C.	78
Cunningham, Jacobi	91	D'Souza, Ian	83
Cunningham, Kathryn	40	Duan, Yinghui	82
Currier, Glenn	38	Duca, Anna	83, 84
Cusin, Cristina	80	Duclos, Catherine	88
Cutler, Andrew	79	Duffy, Ruth	93
Da Costa, Daniel	96	Dujmovic, Tatjana	82
Daigle, Marc	75	Duncan, Wallace	90
Daigneault, Andrée	88	Durgam, Suresh	75, 76, 88, 89, 92, 96
D'Amico, Stephen	79	Du, Yangchun	85, 99
Danchenko, Natalya	81, 93	Earley, Willie	76, 92, 96
Daniel, David	84	Echevarria, Barbara	90
		Edward, Craighead	77

Edwards, Emmeline	55	Frank, Ellen	13, 60
Efros, Mitchell	37, 82	Fraser, Heather	93
Egorov, Michael	75	Freeman, Marlene	24, 49, 63, 99
Ehrhart-Bornstein, Monika	91	Friedmann, Bethanne	78
Ehrich, Elliot	73, 85, 99	Froehlich, Tanya	74
Eliassen, James	76	Fu, Dong Jing	82, 89
Eliaz, Rom	40	Fujita, Masahiro	81
Emily, Stagnaro	77	Furey, Maura	90
Emslie, Graham	89	Furtado, Melissa	87
Engelhardt, Nina	89	Gabbay, Vilma	80, 91
Epstein, Irvin	39, 87	Galvan, Thania	99
Epstein, Jeffery	74	Gama, Clarissa	32, 33, 50
Eramo, Anna	83, 84, 85, 93, 98, 99	Gareau, Melanie	55
Ereshefsky, Larry	93	Garibaldi, George	40
Eriksson, Hans	86	Garnaat, Sarah	79
Etkin, Amit	86	Garner, Rachel	93
Evins, Eden	21	Garzio, Lori	90
Eyerman, David	91	Gasior, Maria	94, 95
Fallu, Angelo	38	Gass, Margery	70
Farchione, Tiffany	9, 18, 21, 23, 31, 48, 64, 72	Gatti, Silvia	73
Farias, Carolina de Paiva	95	Gaudreault, Francois	96
Farokhnia, Mehdi	7, 53	Gauthier, Genevieve	81
Farrell, Adriann	85	Gaynes, Bradley	21, 52, 69
Fava, Maurizio	8, 18, 20, 21, 24, 47, 64, 71, 72, 74, 80, 86, 88, 91, 92, 93	Gazarian, Douglas	79
Feltner, Doug	74	Geesey, Mark E.	77
Ferguson, Paul	96	Gelenberg, Alan	19, 22, 24, 42, 70, 86, 100
Fernandez-Mendoza, Julio	49	Gerard, Elizabeth	56
Fervaha, Gagan	100	Gertsik, Lev	96
Filho, Adriano José Maia	76, 83	Gevorkyan, Hakop	98
Findling, Robert	77	Gillikin, Cindy	88
Fleck, David	76	Glaug, Natalie	78
Fleischhacker, W. Wolfgang	96	Glick, Ira	24, 55, 65
Flint, Alastair J.	81	Gloff, Carol	74
Florea, Ioana	86	Gobbi, Gabriella	75
Flores, Deborah L.	91	Goddard, Simon	94
Fontoura, Paulo	73, 96	Goeders, Nicholas	74
Forbes, Andy	96	Goldberg, Joseph	24, 54
Forero, Giovanna	75	Goldman, Danielle	80
Forma, Felicia	82, 84	Goldman, David	82
Fornal, Aneta	93	Goldman, Robert	42, 73, 77, 97, 100
Forray, Carlos	85	Goldsmith, David	7, 76
Foussias, George	100	Goldsmith, Paul	96
Francois, Clement	81, 93	Gommoll, Carl	75, 88, 92, 93
		Gopal, Srihari	84, 96
		Graff-Guerrero, Ariel	100
		Grandison, Lindsey	23, 31

Greenberg, Benjamin	79	Hundt, Carla	77, 83
Greenberg, Tsafir	86	Hutson, Pete	94
Greer, Tracy	81	Innis, Robert	81
Grigoriadis, Sophie	52	Ionescu, Dawn	7, 80
Grossman, Fred	97	Jack, Allison	42
Grünbauer, Waltraud	73	Jacobsen, Paula	80, 91
Guerguieva, Ralitza	74	Jacobson, William	81
Guerin, Annie	81	James, Thomas	97
Guerin, Glenn	74	Jane, Charles	77
Guiraud-Diawara, Alice	93	Jaso, Brittany	81
Guo, Hua	76, 92	Javitt, Daniel	96
Guthrie, Katherine A.	99	Jiang, Ying	73
Gwynette, M. Frampton	77	Jill, Mast	77
Hagi, Katsuhiko	97	Jin, Fengbin	77, 100
Hallak, Jamie	32	Jin, Na	83, 84, 99
Halperin, Jeffrey	50	Joffe, Hadine	99
Hameed, Ahmad	22, 86, 100	Johnson, Brian	83, 84
Hampson, Aidan	53	Johnson, Clark	79
Han, Jackie	85	Johnson, Robin	88
Hanna, Amira	80, 91	Johnston, Stephen	93
Hansen, Karina	85	Jordan, Robert	73
Harvey, Philip	41, 99	Joshi, Kruti	82
Hatch, Ainslie	78, 82, 84	Julie, Cunningham	79
Hazlett, Erin	82	Kamath, Jayesh	82
Heal, David	91, 94	Kamat, Siddhesh A.	93
Hefting, Nanco	79	Kane, John	13, 24, 60, 84, 97
Hensley, Paula	70	Kapczynski, Flavio	32, 33, 70
Herman, Barry	94, 95	Kapur, Shitij	98
Herman, Merrill	74	Karni, Catherine	89
Hernández-Díaz, Sonia	85	Karp, Jordan	39
Herrmann, Nathan	90	Katzman, Martin	38, 39, 87
Hertel, Peter	85, 99	Keefe, Richard	22, 41, 52, 96
Hildebrandt, Thomas	87	Kelly, Linda	77, 83
Hobart, Mary	82, 92, 96, 98, 99	Kelsh, Debra	93
Hodgkinson, Colin	82	Kemp, Aaron	88
Holtmann, Julia	74	Kerry, Ressler	77
Holt, Stewart	95	Keshaviah, Aparna	94
Holtzheimer, Paul	79	Ketter, Terence	22, 76, 88
Hopkins, Seth C.	73	Khan, Anzalee	41, 53, 78, 84, 89
Hopyan, Talar	78	Khan, Arif	24, 88
Howard, Robert	90	Khan, M. Amin	74
Hoxha, Eriola	97	Khan, Omar	91
Hsu, Jay	98	Kim, Daniel	80
Hubbard, John	80	Kim, Edward	84, 90
Hudson, James	94, 95	Kim, Sanghyeon	97
Hughes, Erica	83	Kinon, Bruce	23, 31
Hui-Chin, Hsu	77	Kirkpatrick, Brian	41
Hummel, Rebecca	90	Kishimoto, Taishiro	97

Klassen, Larry	38	Liebowtiz, Michael	43, 74
Knights, Jonathan	78, 84	Light, Gregory A.	83
Knowles, Nadine	93	Lima, Camila Nayane	76
Koblan, Kenneth S.	73, 100	Lindenmayer, Jean-Pierre	65, 84
Kocsis, James H.	20	Lingohr-Smith, Melissa	82
Kolb, Hartmuth	81	Lin, Jay	82
Kollins, Scott H.	100	Lippman, Marc	41
Ko, Mancia	94, 95	Lipschitz, Alan	76
Komorowsky, Andrew	78	Liss, Charles	80, 92
Kornstein, Susan	92	Litten, Raye	20
Korszen, Stephanie	88	Liu, Kuan	90
Kott, Alan	79, 84, 89	Llosa, Teobaldo	75, 87
Krishnamurthy, Venkatesh	76, 86, 100	Loebel, Antony	73, 76, 77, 85, 88, 89, 93, 97, 98, 99, 100
Kroger, Hans	88, 89		
Kruesi, Marcus	77	Loft, Henrik	81, 86
Krystal, Andrew	71, 80	Lombardo, Ilise	96
Kung, Simon	79	Lophaven, Søren	81
Kupfer, David	20, 44	Lovat, Maxim	75
Kwiatkowski, Molly	85	Loze, Jean-Yves	85
Laezza, Fernanda	97	Lu, Kaifeng	89, 96
Lakdawalla, Darius	82	Lucic, Luka	89
Lam, Jonathan	78	Luckenbaugh, David	90
Landbloom, Ronald	77, 83	Macaluso, Matthew	78
Landinez, Johanna	92	Macêdo, Danielle	50, 76, 83, 95
Lapid, Maria	79	Macek, Tom	96, 98
LaPorte, Scott	80, 92	MacEwan, Joanna	82
Larsen, Frank	99	Machado, Michel de Jesus S.	76, 83
Laszlovszky, István	76, 92, 96	Machado-Vieira, Rodrigo	81
Laughren, Thomas P.	20, 22	Mackle, Mary	77, 83
Lawson, Erica	78	Madhusoodanan, S.	92
Layne, Jennifer	85, 99	Mago, Rajnish	93
Leavitt, Molly	74	Mahableshwarkar, Atul	86, 91, 92
Lebowitz, Barry	90	Malhotra, Anil	20, 22
Ledon, Fred	79	Malla, Ashok	85
Lee, Frances	77	Mamdani, Muhammad	90
Lee, Jimmy	100	Mamo, David	100
Lee, Jing-Huei	76	Mancevski, Branislav	90
Lee, Sang	93	Mancione, Linda	85
Legacy, Susan	93	Mancuso, Jessica	96
Lenze, Eric	77	Manji, Husseini	10, 19, 20, 59, 60
Leonard, Sean	90	Manning, Raymond	85
Leslie, Kimberly	87	Mao, Lian	90
Leuchter, Andrew	73	Mao, Xiangling	80
Leucht, Stefan	97	Mao, Yongcai	77
Leung, Jonathan	79	Marder, Stephen	20, 22, 65, 84, 96
Lewin, Roxanne	74	Marfurt, Samantha	85
Licinio, Julio	91	Mariano, Timothy	7, 79
Li, Dayong	96		

Markovtsova, Lada	78	Moskal, Joseph R.	74
Mark, Winifred	92	Moustafa, Danna	85, 99
Marshall, Fiona	40	Mukhametshina, Elvira	75
Masotti, Matt	89	Mullen, Jamie	80, 92
Mates, Sharon	99	Mulsant, Benoit H.	81, 100
Mathew, Sanjay	43, 74	Multach, Matthew	79
Mathews, Maju	75, 77, 83, 88	Murphy, Michael	78
Matsushima, Yuki	94	Murphy, Shannon	85
Matz, Jørgen	92	Murray, Michael	42
Mayes, Taryn	89	Muser, Erik	82
Mazhari, Reza	93	Naber, Dieter	85
McDonald, Daniel	55	Nagamizu, Kazuhiro	83, 85
McDonald, William	79	Nakamura, Richard	17, 62
McElroy, Susan	94, 95	Narayan, Vaibhav	11, 60
McEvoy, Joseph	51	Nasrallah, Henry	85, 98
McGrath, Patrick	86	Nelson, Craig	20, 22, 54, 92
McGurk, Susan	84	Nelson, Sarah	79
McInenery, Kathryn	85	Nemeroff, Charles	41
McInnis, Melvin	86	Németh, György	76, 92, 96
McIntyre, Roger	77, 81, 83	Nenov, Miroslav	97
McIver, Lindsey	75	Nesbit, Omaira Meléndez	92
McMahen, Russ	75, 87	New, Antonia	82
McMorrow, Donna	93	Newcomer, John	24, 77, 85, 89, 98
McQuade, Robert	83, 84, 96, 99	Newcorn, Jeffrey	49, 50, 87
Meighan, Sean	78	Nguyen, Charles	95
Meisels, Peter	80	Nicholas, Timothy	96
Menard, François	80	Niciu, Mark	81, 90
Menard, William	94	Nicolato, Rodrigo	33
Menon, Mahesh	100	Nicol, Ginger	77
Merikle, Elizabeth	81, 93	Nierenberg, Andrew A.	20
Meyer, Matt	78	Niggli, Markus	73
Meyer, Roger	86, 100	Nitta, Masahiro	97
Meyers, Barnett	39, 81	Norris, Matthew	76
Michelson, David	20	Nuamah, Isaac	96
Miller, Andrew	43	Nunez, Rene	75
Miller, Brian	76	Nyilas, Margaretta	78, 96
Millet, Robert	94	Nylander, Anna-Greta	83, 85, 99
Mimura, Masaru	90	Oelke, Alisha	78
Mischoulon, David	54	Ogasa, Masaaki	99
Mitchell, Michael	86, 100	O’Gorman, Cedric	99
Mittoux, Aurelia	80	Okame, Takao	94
Mohamed, Munira	87	Okusaga, Olaoluwa	97
Mohite, Satyajit	97	Olsen, Christina	81
Monte, Aline	50, 76, 83, 95	Olsen, Emily	87
Montero, Ulises	88	O’Malley, Stephanie	20
Montoya, Ivan	23, 31, 40	Onojighofia, Tobore	80
Moore, Christine	69	Opler, Mark	40, 69, 78, 89
Moore, Rema	73	Oquendo, Maria	86

Osman, Douglas	90	Raoufinia, Arash	99
Østergaard, Søren Dinesen	7, 81	Rapaport, Mark	19, 23, 24, 31, 49,
Ota, Ai	83, 91, 94		76
Otero, Gloria	88	Rasmussen, Steven	79
Ouyang, John	84, 96, 98	Ravan, Sarah	77
Palo, William	92	Reeves, Suzanne	90
Pani, Luca	9, 18, 48, 72	Reider, Aubrey	76
Papakostas, George	64, 88	Remington, Gary	100
Paquet, Jean	88	Renner, Deborah	90
Park, Minkyung	81	Ressler, Kerry	88
Parsaik, Ajay	97	Rethorst, Chad	81
Parsey, Ramin	86	Reynolds, Charles	39
Patenaude, Brian	86	Ricardo, Josefina	88
Paterson, Blake	93	Ricart, Thomas	91
Pathak, Sanjeev	73	Richards, Erica	7, 81, 90
Patrick, Pauline	77	Risinger, Robert	85, 99
Pavshincev, Vladimir	75	Rive, Benoît	81, 93
Pawaskar, Manjiri	95	Robinson, Delbert	51
Pencina, Michael	88	Rock, Colleen	78
Pendergrass, Jo	93	Rodrigues, Francisca Taciana	76, 83, 95
Perez, Vanessa	81, 93	Rodriguez-Perez, Mercedes	82
Perrett, John	78	Roffman, Joshua	52
Perry, Pamela	83, 84, 85, 91, 94	Rohatagi, Shashank	78, 84
Peters-Strickland, Timothy	78, 83, 84, 85, 99	Romano-Silva, Marco	32
Pfister, Stephanie	96	Rommel, Jeffrey	90
Phillips, Katharine	22, 23, 31, 94	Rosenbaum, Jerrold	22
Phillips, Mary	86	Rosenstein, Lia	79
Pikalow, Andrei	76, 77, 85, 89, 97,	Rothman, Brian	78, 89
	98	Rothschild, Anthony J.	81
Pliego, Bernardo	88	Roussos, Panos	82
Pollock, Bruce	100	Rowley, Helen	91
Pope, Laura	93	Roy, Marcela	79
Popoola, Olusegun	97	Rubin, Jonathan	42, 73
Potkin, Steven	55, 65, 85	Ruth, Adam	88, 89
Potter, William	20, 44, 71	Ryan, J. Michael	85
Pottorf, William	80, 92	Sacchetti, Benedetto	97
Prakash, Ajay	79	Sachs, Gary	79
Preskorn, Sheldon	78	Saillard, Jelena	99
Proffit, Deborah	78	Sajatovic, Martha	22
Pyke, Robert	99	Sakurai, Hitoshi	7, 98
Queiroz, Ana Isabelle de Góis	76, 83, 95	Saltz, Bruce	22
Quiroz, Jorge	73	Salvadore, Giacomo	81
Rabinowitz, Jonathan	37, 53	Sambunaris, Angelo	93
Radewonuk, Jana	94, 95	Samsonov, Michael	75
Rajagopalan, Krithika	76	Sanacora, Gerard	64, 74
Rajji, Tarek	100	Sanchez, Raymond	83, 84, 96
Rana, Brinda K.	83	Sanders, Jeff	7, 88
Ranganathan, Rajesh	16, 62	Santarelli, Luca	73, 96

Sanwald-Ducray, Patricia	73	Spratt, Eve	77
Sapin, Christophe	85	Stankovic, Srdjan	73, 85, 99
Sarah, Juul	77	Stannard, Beth	79
Sarampote, Christopher	19, 23, 31	Stark, Jeffrey	75, 87
Sarma, Kaushik	100	Stein, Mark	49, 87
Saunders, Erika	22, 49, 53, 76	Sternat, Tia	87
Saury, Sybille	88	Stevenson, Bernadette	88
Savitz, Jonathan	78	Stikic, Maja	88
Scherer, Ethan	82	Stout, Robert	94
Schlechte, Janet	74	Stover, Amanda	76
Schneider, Bret	79	Strakowski, Stephen	76
Schoneberg, Sabrina	82	Su, Zengliu	95
Schooler, Nina	5, 21, 23, 31, 48, 51, 54, 97	Sugaya, Kensaku	85
Schwarz, Dan	80	Suppes, Trisha	93
Scranton, Victoria	82	Suzuki, Takefumi	90, 98
Sedway, Jan	69	Swartz, Holly	19, 21, 22, 23, 31, 62
Selvaraj, Sudhakar	71	Swordlow, Neal R.	83
Setnik, Beatrice	78	Szpindel, Isaac	87
Shafrin, Jason	82	Takeuchi, Hiroyoshi	7, 100
Shapero, Benjamin	91	Talledo, Jo A.	83
Shariff, Salimah	90	Tamburri, Paul	43, 73
Shawkat, Adnan	82	Tamm, Leanne	74
Sheehan, David	75, 81, 94, 95	Tan, Ye	96
Shelton, Richard	22, 80, 88, 93	Tangu, Marie-Louise	97
Shepherd, Shaina	90	Tang, Xiongwen	75, 88
Shin, Paul	79	Targum, Steven	93
Shiovitz, Thomas	37, 82	Tatsumi, Kazu	78
Shungu, Dikoma	80	Teixeira, Antonio	33
Shurtleff, David	16, 55, 62	Tempia, Filippo	97
Siever, Larry	82	Temple, Robert	10, 48
Siffert, Joao	79, 93	Tengler, Mark	75, 87
Sikes, Carolyn	75, 87	Teter, Christian	75
Silva, Robert	77, 88, 93, 97	Thase, Michael	14, 19, 21, 24, 61, 86, 93
Silverman, Bernard	44, 54, 73, 85, 99	Theresa, Nguyen	77
Simeonova, Diana	7, 77	Tillisch, Kirsten	55
Singh, Jaskaran	43, 74	Toby, Goldsmith	77
Sit, Dorothy	56	Tocco, Michael	98
Siu, Cynthia	76, 85, 97, 99	Todtenkopf, Mark	73
Skolnick, Phil	15, 21, 40, 62	Torres, Rosarelis	85
Skuban, Aleksandar	82, 84, 86, 92, 98, 99	Touloupoulou, Timothea	92
Sliwa, Jennifer Kern	95	Toupin, Jean	75
Smith, Thomas	94, 95	Trinh, Nhi-Ha	91
Snow-Adami, Linda	77, 83	Trivedi, Madhukar	21, 64, 81, 86, 93, 94
Soares, Jair	71	Trombello, Joseph	81
Sosinsky, Alexandra	85	Tsai, Joyce	77, 88, 89
Spana, Carl	73		

Tsai, Max	96, 98	Whyte, Ellen M.	81
Tsuneyoshi, Kana	91, 94	Wilfley, Denise	94
Tudhope, Rebecca	79	Wilhelm, Sabine	94
Turecki, Gustavo	75	Williams, Janet	90
Turkoz, Ibrahim	84, 89	Williams, John	77
Uchida, Hiroyuki	90, 98	Williamson, David	77
Uhde, Thomas W.	87	Wisner, Katherine	56
Umbricht, Daniel	44, 73, 96	Wolanski, Kristy	89
Vachon, Jeanne	75	Wolfe, David	99
van Os, Jim	92	Wolfgang, Curt	85
Vanover, Kimberly	99	Wong, Ma-Li	91
Vasconcelos, Silvânia Maria	95	Woster, Patricia	94, 95
Vasudev, Akshya	90	Wout, Mascha van't	79
Vasudev, Kamini	79	Wright, H.H.	77
Vickers, Steve	94	Wu, Helen	82
Vieta, Eduard	86	Wu, Xiao	77, 83
Viguera, Adele	85	Wurfel, Brent	78
Vince, Bradley	93	Xie, Jinhui	96, 98
Virginia, Thompson	79	Xie, Lin	95
Vitiello, Benedetto	21, 22	Yang, Lawrence	40
Voineskos, Aristotle	100	Yatham, Lakshmi N.	76
Voort, Jennifer Vande	90	Yavorsky, Christian	89
Vora, Anvi	7, 82	Yeung, Albert	91
Wagner, Karen	24, 63	Yingling, Michael	77
Walker, N. Robrina	81	Yonan, Charles	79
Walls, Tessa	81	Yonkers, Kimberly	23
Walsh, Emily	79	Yoshida, Kazunari	7, 90
Walz, Roger	32	Young, Jared W.	83
Wang, Betty	99	Young, Robert	39
Wang, Chao	93	Youngstrom, Eric	86, 100
Wang, Zhixiao	95	Youssef, Eriene	96
Waninger, Shani	88	Yu, Wen	74
Warren, Ryan	75	Yuan, Jeffrey	78
Watabe, Kei	97	Yuan, Quiaoping	82
Webster, Maree	97	Zalcman, Steven	14, 62, 71
Weiden, Peter	85, 99	Zammit, Gary	37
Weiller, Emmanuelle	81, 82, 83, 84, 85, 86, 91, 92, 94, 96, 98, 99	Zanotti-Fregonara, Paolo	81
Weingard, Kerri	37, 82	Zarate, Carlos	21, 23, 42, 54, 63, 81, 90
Weingart, Michal	99	Zeller, Scott	38
Weisler, Richard	94	Zemel, Babette	74
Weiss, Catherine	81, 82, 84, 86, 91, 92, 98, 99	Zhang, Peter	81, 82, 86, 91, 92, 99
Weissman, Myrna	86	Zhao, Cathy	83, 84
Welge, Jeffrey	76	Zheng, Hanzhe	98
Wheeler, Josephine	90	Zhong, Wei	80, 91
White, Amanda	86, 100	Zia, Zainab	89
		Zimmerman, Mark	52, 79

Zisook, Sidney	24
Zohar, Joseph	44
Zou, Zhifeng	82
Zukin, Stephen	89
Zummo, Jacqueline	85, 99



Fairmont
SCOTTSDALE PRINCESS



Save the Date:
2016 ASCP Annual Meeting
May 30 – June 2, 2016
Scottsdale, Arizona



ASCP
AMERICAN SOCIETY OF
CLINICAL PSYCHOPHARMACOLOGY
www.ascpp.org

ASCP Executive Office
5034A Thoroughbred Lane
Brentwood, Tennessee 37027

phone: 615-649-3085
fax: 888-417-3311
email: info@ascpp.org